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ABSTRACT 
Background and aim: Gait deviations in individuals with Rheumatoid Arthritis (RA) and 
Juvenile Idiopathic Arthritis (JIA) have previously been demonstrated as a consequence of 
active disease. During the last decade, pharmacological treatments have dramatically 
improved outcomes but the effect on gait dynamics is not fully understood. The overall aim 
of this thesis was to enhance the understanding of the effect of pharmacological 
interventions on gait dynamics in individuals with RA and JIA. Moreover, we aimed to 
evaluate the usability of measures of overall gait quality which could facilitate future 
comparisons between groups and after interventions. In Study I the aim was to evaluate the 
usability of the Gait Deviation Index (GDI) as a measure of overall gait quality in adults with 
RA. The aim of Study II was to determine the effects of anti-Tumor Necrosis Factor Alpha 
(TNF-α) treatment on gait dynamics in individual with RA. Study III aimed to evaluate the 
occurrence, clinical characteristics and prognostic factors associated with ankle arthritis in 
children with JIA. The aim of Study IV was to evaluate the effects of Intra-Articular 
Corticosteroid Injections (IACI) in the foot on gait dynamics and patient-relevant outcomes 
in children with JIA. 
Participants and methods: In Study I, 63 adults with RA and 59 healthy controls were 
included in a retrospective and cross-sectional study. Gait dynamics, obtained by three 
dimensional (3D) gait analysis and represented by the GDI, were analyzed and related to 
walking speed, physical disability and pain. In Study II, 16 adults with RA were included, and 
gait dynamics, obtained by 3D gait analysis, and disease characteristics were analyzed at 
baseline and three months after anti-TNF-α treatment. In Study III, 440 children with JIA 
were followed for the first eight years of disease in a population based cohort. The 
occurrence of ankle arthritis was assessed and related to clinical characteristics, and to 
disease outcome. In Study IV, 43 children with JIA were included and followed for three 
months after foot IACI treatment. Gait dynamics and disease characteristics were assessed 
at baseline, and at three weeks and three months after treatment. 
Results: In Study I, the GDI was found to be a useful measure of overall gait quality in 
individuals with RA. In Study II, treatment with anti-TNF-α improved gait dynamics in adults 
with RA, but significant gait deviations were still present after treatment. In Study III, ankle 
arthritis was found to be common in JIA, related to a polyarticular disease course in young 
children, and was associated with failure to achieve remission. In Study IV, as a result of IACI 
treatment improvements were identified in foot-related disability and inflammatory joint 
symptoms, but gait dynamics were unchanged.  
Conclusion: We recommend the use of measures of overall gait quality, such as the GDI, to 
quantify gait deviations in individuals with RA and JIA. This measure adds an aspect of 
dynamic function to arthritis care and facilitates comparisons of gait dynamics between 
groups or over time and between gait dynamics and other types of outcome measures. Gait 
deviations persist despite pharmacological treatment, indicating that the biomechanical 
perspective is important when evaluating walking disability. Ankle arthritis is common in JIA, 
predicts a polyarticular disease course in young children and is associated with failure to 
achieve remission. We suggest that ankle arthritis should be taken into account in the 
assessment of prognosis and choice of treatment strategy in JIA. 
  
LIST OF SCIENTIFIC PAPERS 
The thesis is based on the following original articles and manuscripts. Every paper will be 
referred to in the text by its Roman numerals. 
 
I. Esbjörnsson A-C, Rozumalski A, Iversen MD, Schwartz MH, Wretenberg P, 
Broström EW. Quantifying gait deviations in individuals with Rheumatoid 
Arthritis using the Gait Deviation Index. Scandinavian Journal of 
Rheumatology. 2014;43:124-131 
 
II. Broström EW, Esbjörnsson A-C, Von Heideken J, Larsson P, Wretenberg P, 
Iversen MD. Change in gait deviation index after anti-tumor necrosis factor-
alpha treatment in individuals with rheumatoid arthritis: A pilot study. 
Scandinavian Journal of Rheumatology. 2013; 42: 356-361 
 
III. Esbjörnsson A-C, Aalto K, Broström  EW, Fasth A, Herlin T, Nielsen S, Nordal 
E, Peltoniemi S, Rygg M, Zak M, Berntson L on behalf of the Nordic Study 
Group of Pediatric Rheumatology (NoSPeR). Ankle arthritis predicts poly-
articular disease course and unfavorable outcome in children with Juvenile 
Idiopathic arthritis. Submitted. 
 
IV. Esbjörnsson A-C, André M, Iversen MD, Hagelberg S, Schwartz MH, Broström 
EW. Effect of intra-articular corticosteroid foot injections on walking function 
in children with juvenile idiopathic arthritis. Submitted. 
  
CONTENTS 
1 Introduction .................................................................................................................... 1 
1.1 Gait deviations in individuals with juvenile idiopathic arthritis and 
rheumatoid arthritis  ............................................................................................ 2 
1.2 Juvenile idiopathic arthritis and rheumatoid arthritis ....................................... 4 
1.2.1 Juvenile idiopathic arthritis ....................................................................... 5 
1.2.2 Rheumatoid arthritis ................................................................................. 7 
1.3 Treatment management ...................................................................................... 8 
1.4 Measuring gait dynamics ...................................................................................... 9 
1.4.1 Three dimensional gait analysis ................................................................ 9 
1.5 Rationale for this thesis ...................................................................................... 12 
1.6 Aims ..................................................................................................................... 13 
2 Methods ........................................................................................................................ 15 
2.1 Study outlines ...................................................................................................... 15 
2.2 Participants and data collection ........................................................................ 16 
2.3 Evaluation methods and outcomes ................................................................... 20 
2.3.1 Measuring gait dynamics ........................................................................ 20 
2.3.2 Measuring pain ........................................................................................ 23 
2.3.3 Measuring physical disability .................................................................. 23 
2.3.4 Measuring foot-related disability ........................................................... 23 
2.3.5 Measuring disease characteristics .......................................................... 24 
2.4 Statistical methods and data analysis ............................................................... 24 
2.5 Ethical considerations ......................................................................................... 27 
3 Results and discussion ................................................................................................... 29 
3.1 General ................................................................................................................ 29 
3.2 Results .................................................................................................................. 30 
3.2.1 Ankle arthritis in JIA ................................................................................ 30 
3.2.2 Measures of gait dynamics ..................................................................... 33 
3.2.3 Effect of pharmacological treatment on gait dynamics ........................ 37 
3.2.4 Gait quality in relation to walking speed, pain, disease activity, 
and physical disability ............................................................................. 40 
3.3 Methodological considerations ......................................................................... 44 
3.3.1 Samples and study designs ..................................................................... 44 
3.3.2 Measuring gait dynamics ........................................................................ 44 
3.3.3 Measuring physical disability and pain ................................................... 46 
3.4 Statistical considerations .................................................................................... 46 
3.5 Limitations ........................................................................................................... 47 
3.6 Conclusions and clinical implications ................................................................ 48 
3.7 Future perspectives ............................................................................................ 48 
4 Acknowledgements ...................................................................................................... 51 
5 References ..................................................................................................................... 55 
 
  
LIST OF ABBREVIATIONS 
3D GA Three Dimensional Gait Analysis 
ACR  American College of Rheumatology 
ANA  Anti-nuclear antibody 
ANOVA Analysis of Variance 
CHAQ Child Health Assessment Questionnaire 
CI  Confidence Interval 
CRP  C - Reactive Protein 
DAS28 Disease Activity Score 28 joint count   
DMARD Disease-Modifying AntiRheumatic Drugs 
ELISA  Enzyme-Linked ImmunoSorbent Assay 
ESR  Erythrocyte Sedimentation Rate 
GDI  Gait Deviation Index  
GDI-k  Gait Deviation Index- Kinetic 
HAQ   Health Assessments Questionnaire Disability Index 
HLA-B27 Human Leucocyte Antigen B27 
IACI  Intra-Articular Corticosteroid Injections 
ICC  Intraclass Correlation Coefficient 
ICF  International Classification of Functioning, Disability and Health 
ILAR  International League of Associations for Rheumatology 
JAFI  Juvenile Arthritis Foot disability Index 
Nd  Non-Dimensional, Dimensionless 
NoSPeR Nordic Study group of Pediatric Rheumatology 
RA  Rheumatoid Arthritis 
RF  Rheumatoid Factor 
SD  Standard Deviation 
SEM  Standard Error of Measurement 
TNF-α Tumor Necrosis Factor-alpha 
US  Ultra Sound 
VAS  Visual Analogue Scale 
 
 
 
  
  
THESIS AT A GLANCE 
Study Aim Method Results Conclusions 
 
 
 
 
I 
To evaluate the 
usability of the GDI 
as a measure of 
overall gait quality 
in adults with RA. 
Retrospective case- 
control analysis of 63 
adults with RA and 59 
healthy controls. Using 
3D gait analysis, gait 
deviations, represented 
by the GDI, were 
analyzed relative to 
typical gait patterns, 
walking speed, physical 
disability and pain. 
Adults with RA showed gait 
deviations as compared to 
healthy controls with a mean 
GDI about 1.3 SD away from 
normal gait. A change of 5 GDI 
units was required to account 
for natural variation in gait on 
an individual level. Level of gait 
deviations was to some extent 
related to walking speed but 
not to physical disability or pain. 
GDI appears to be a useful 
measure of overall gait 
quality in adults with RA 
and may help clinicians 
understand the 
relationship between RA, 
gait deviations and walking 
disability.  
 
 
 
 
II 
To determine the 
effects of anti-TNF-α 
treatment on gait 
dynamics in 
individual with RA. 
A pre-post design study 
including 16 adults with 
RA. Gait dynamics were 
analyzed after 3 month 
of anti-TNF-α treatment 
relative to disease 
characteristics.  
As a result of treatment both 
the GDI and GDI-kinetic 
improved on average by about 4 
GDI units. Disease activity, 
physical disability (HAQ) and 
pain during walking improved 
significantly after treatment.  
Treatment with anti-TNF-α 
improved gait dynamics in 
adults with RA but 
significant gait deviations 
were still present after 
treatment. Thus, gait 
dynamics is an important 
aspect to consider in 
treatment evaluations. 
 
 
 
 
III 
To evaluate the 
occurrence, clinical 
characteristics and 
prognostic factors 
associated with 
ankle arthritis in 
children with JIA. 
440 children with JIA, 
all ILAR categories, 
were followed for eight 
years of disease in a 
longitudinal population 
based cohort (NoSPeR). 
Occurrence of ankle 
arthritis was assessed 
and related to clinical 
characteristics, and 
outcome of diseases. 
251(57%)children experienced 
ankle arthritis during the first 
eight years of disease. Ankle 
arthritis was least common in 
the persistent oligoarticular 
category (25%) and most 
common in polyarticular 
categories (83-85%).  Children 
who developed ankle arthritis 
early were younger at disease 
onset and had an increased risk 
of a higher number of 
cumulative involved joints and 
for not achieving remission. 
Ankle arthritis is common 
in JIA. Early ankle arthritis 
predicts a polyarticular 
disease course in young 
children and is associated 
with failure to achieve 
remission eight years after 
disease onset. We suggest 
that ankle arthritis should 
be recognized in the 
assessment of prognosis 
and choice of treatment 
strategy in JIA. 
 
 
 
 
 
IV 
To evaluate the  
effects of IACI 
treatment on overall 
gait dynamics and 
patient-relevant 
outcomes after 3 
weeks and 3 months 
in children with JIA 
with foot and ankle 
synovitis.  
43 children with JIA 
were followed over 3 
months in a prospective 
intervention study. 
Using 3D gait analysis 
gait dynamics and self-
reported physical 
(CHAQ) and  foot-
related (JAFI) disability 
were analyzed. 
Foot-related disability and 
inflammatory joint symptoms 
improved following treatment. 
Gait dynamics were 
compromised before treatment 
and did not improve following 
treatment.  The ability to 
generate ankle power during 
walking and ankle /hip power 
ratio was reduced, indicating a 
power shift from the ankle to 
the hips, more prominent in 
children with polyarthritis.  
Improvements in foot-
related disability and 
inflammatory joint 
symptoms but not in gait 
dynamics were identified 
as a result of IACI 
treatment. Children with 
polyarticular disease and 
those scoring more 
difficulties with walking 
prior to treatment had the 
worst outcome and should 
be monitored carefully 
following intervention  
 
  
  
  
 
1 INTRODUCTION 
During the last decade, pharmacological treatments have dramatically improved outcomes 
in individuals with Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA); reduced 
disease activity and clinical remission are the paramount goals 1. Reduced disease activity 
facilitates an active lifestyle that is vital for individuals with inflammatory joint disease, both 
to reduce the impact of arthritis-associated comorbidities and to benefit from the positive 
effects of physical activity on general health and fitness 2. A common, easy accessible, low-
cost way of being physically active is to walk 3. However, walking disability is common 
among individuals with RA and JIA and is rated as a disability that is very important to 
improve 4, 5.  
The main focus of this thesis is on gait dynamics, one of several perspectives on walking. 
According to the International Classification of Functioning, disability and health (ICF) a clear 
distinction between walking and gait can be drawn. In their definition, which is the 
definition also used in this thesis, “walking” refers to mobility or the ability to move around 
and is a component of activity (Figure 1) 6. As the title of this thesis implies, walking is 
multifaceted and several factors contribute to walking ability. One of these factors is gait 
pattern function. In this thesis focus is on gait patterns measured in a motion analysis 
laboratory. The word “gait” refers to the “quality of walking” and is classified as a 
component of body function. 
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Figure 1. The international classification of functioning, disability and health (ICF) provides a 
framework for the description of health and health-related states within which measures of 
gait and walking can be identified and sorted 6. 
 
 
1.1 GAIT DEVIATIONS IN INDIVIDUALS WITH JUVENILE 
IDIOPATHIC ARTHRITIS AND RHEUMATOID 
ARTHRITIS 
In individuals with RA approximately 60% experience walking disability at disease onset, and 
after the initial years of disease, walking disability stabilizes with a prevalence of around 
40% 7. Walking ability is complex, and several components contribute to walking disability 
such as: pain, pathology, psychology, and environmental factors 8. Studies of gait dynamics 
have the potential to reveal insights into factors contributing to walking disability 8. Gait 
deviations in RA and JIA have been associated with disease activity 9-11, deformity 12, 13 and 
pain 14. In adults with knee osteoarthritis the quality of waking itself has been related to the 
progression of disease 15. Despite a growing body of studies evaluating gait quality in 
individuals with RA and JIA, the association between gait deviations, disease progression 
and walking disability is unclear 16.  
Gait deviation is a common finding in individuals with RA and JIA and both inflammatory 
(swelling, pain, and stiffness) and mechanical (joint destruction and deformity) factors are 
known to lead to primary and compensatory gait deviations 17, 18.  To avoid loading painful 
joints, individuals with RA and JIA typically adapt a gait pattern characterized by reduced 
walking speed, cadence and stride length 13, 19. Other common gait deviations seen in 
individuals with RA and JIA are longer weight bearing periods on both feet and a reduced 
range of motion, joint moment and joint power (Figure 2) 10, 11, 20-23. 
Introduction 
 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Example of gait deviations at the ankle joint from a child with JIA and bilateral foot 
involvement. Each graph represents a gait cycle with the first 60% representing stance phase 
and last 40% swing phase. In the graphs, stance and swing are visually separated by a 
vertical black line. The shadowed areas represent the mean and 1 SD of healthy controls. 
Solid line; left side, dashed line; right side. Impairments are seen with reduced dorsiflexion on 
the left side at the second half of the stance phase, possibly due to knee arthritis (A), with 
corresponding reduction in plantar flexion moment (B). Plantarflexion on the right side is 
reduced in the transition phase from stance to swing (A) with corresponding reduction in 
ankle power (C). Also note the prolonged stance phase time, represented by the later peak 
values in the child with JIA compared to healthy controls. 
 
 
There is limited knowledge of the possible effects of today´s potent medical treatments on 
gait dynamics in individuals with RA and JIA. The effect of pharmacological intervention on 
gait dynamics was analyzed as early as 1983 24 but despite recent advances in 
pharmacological therapy, only a few studies have evaluated gait dynamics following 
pharmacological interventions in RA and JIA since then 10, 25-28.  Two of these studies were 
first published in 2013 and evaluated the effect of anti-Tumor Necrosis Factor alpha (TNF-α) 
treatment on gait dynamics in adults with RA, one of them being Study II in this thesis 25, 27. 
In both studies, reduction of disease activity was accompanied by improvements in gait 
dynamics including increased walking speed, stride length, ranges of motion and ability to 
load the joints. However, gait deviations persisted despite treatment with anti-TNF-α 25, 27.  
 
Previous work has identified improved gait dynamics as a result of Intra-Articular 
Corticosteroid Injections (IACI) treatment in adults with RA 28 and in children with JIA 10. The 
effects of IACI on gait dynamics have also been documented in adults with osteoarthritis in 
the knee 29, 30. Broström and co-workers evaluated the effect of IACI treatment in any lower 
extremity joint in children with JIA 10. In their study gait dynamics in both treated and 
untreated joints improved as a result of treatment. Their study was conducted at the very 
beginning of the era of biologic therapy and included a small sample size with a three week 
follow-up. To expand on the results from Broström´s study, we chose a longer follow-up 
period for our study and evaluated gait dynamics over a period of three months following 
foot IACI in a pharmacologically well-managed cohort (Study IV). 
 
A B C 
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The relationship between gait deviations and walking disability in RA and JIA is not fully 
understood and several components contribute to walking disability. The goals of this thesis 
are to evaluate whether gait deviations persist after pharmacological treatments and to 
evaluate the usability of measures of overall gait quality in individuals with RA and JIA. The 
relation between gait deviations and walking disability is considered and discussed but was 
not the main focus of this thesis.   
1.2 JUVENILE IDIOPATHIC ARTHRITIS AND 
RHEUMATOID ARTHRITIS 
RA and JIA are two different diseases with several common features 31. RA and JIA are 
inflammatory diseases mainly affecting the joints. The hallmark of RA and JIA is arthritis with 
inflammation of the synovial membrane (synovitis), characterized by swelling, tenderness 
and restricted ranges of motion 31. Most joints in the body are at potential risk of arthritis-
associated inflammation. In children with JIA, large joints, such as the knee, ankle and wrist, 
are most commonly involved 32 whereas in adults with RA, peripheral joints in the hand or 
foot are predominantly effected 31. Disease pathophysiology is characterized by infiltration 
of immune cells such as B cells, T cells, inflammatory macrophages, neutrophils and mast 
cells, eventually leading to joint tissue destruction with bone erosion by osteoclasts and 
degradation of cartilage by proteases 33. The definition of active arthritis as defined by the 
pediatric association of the International League of Associations for Rheumatology (ILAR), is 
based on clinical findings of joint swelling, or a limited range of joint mobility with pain or 
tenderness 34. Whereas in the American College of Rheumatology (ACR) from 1987, the 
criterion for arthritis is based on joint swelling 35.  
Pain is the most common symptom of RA as well as JIA, and has been associated with sleep 
disturbances, functional disability, and psychosocial distress 36 and may continue despite 
inactive disease 37. Both JIA and RA commonly follow an unpredictable disease course 
fluctuating between phases of active disease and remission 38, 39. Remission criteria have 
varied over time as have the percentages of individuals achieving remission. It is estimated 
that about 50% of children with JIA achieve remission within five years 40 and about 40% 
have continued disease activity 30 years after disease onset 41. In adults with RA, the 
percentage of patients achieving remission is lower, but it is concluded that it is easier to 
achieve sustained remission today than it was a decade ago 42.  
JIA and RA have a profound effect on an individual’s situation and affect both physical and 
emotional aspects of functioning as well as health-related quality of life 31, 43. Both JIA and 
RA are associated with comorbidities. In children with JIA, comorbidities such as low bone 
mass 44, increased risk of fractures 45, early onset of osteoporosis 46, 47, bone growth 
disturbances 48, uveitis 49 and fatigue 43 have been reported. Furthermore, there is an 
elevated cardiovascular disease risk, especially for those children with continued disease 
into adulthood 50. In adults with RA, an increased risk of fatigue 31, as well as hypertension, 
osteoporosis, osteoarthritis, hyperlipidemia 51, and mortality from cardiovascular disease 52 
are reported. In both RA and JIA, inflammation around affected joints leads to muscular 
weakness 53, 54, which may even persist when the disease is inactive 55, 56. In adults with RA 
the combination of progressive joint damage and continuing functional decline 57, 58 may 
lead to activity limitations and participation restrictions in daily life 59. Thus, there are many 
reasons for individuals with JIA and RA to stay physically active. Given the high frequency of 
Introduction 
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individuals with RA reporting walking disability 7, it is imperative to explore contributing 
factors, such as gait deviations. 
1.2.1 Juvenile Idiopathic Arthritis 
JIA is the most common rheumatic disease of childhood and is a major cause of short term 
and long term disability 60. JIA does not refer to a single disease, but to all forms of arthritis 
that begin before 16 years of age, persist for more than six weeks and are of unknown 
etiology 34. Both genetic and environmental factors are thought to contribute to disease 
onset 61-63. The annual incidence of JIA in Sweden is estimated to be 11-15 per 100,000 
children/year, which means that about 200-250 new children develop JIA annually 49, 64. In 
total, there are about 1,200-1,700 children with JIA under the age of 18 in Sweden 60. Girls 
are more frequently affected than boys with a gender ratio of about 2-3:1 49. For girls there 
is a peak onset at 1-3 years of age whereas the age of onset among boys is more evenly 
distributed throughout childhood 49, 64. In pediatric rheumatology, the classification criteria 
have varied between countries and over time making population comparisons difficult. The 
most recent classification criteria, and the criteria used in this thesis, is the ILAR 
classification which classifies JIA into seven different categories. This classification criteria 
has been stated to be a “work in progress” rather than a static framework (Table I) 34.   
Ankle arthritis in JIA  
Study III evaluates the occurrence, clinical characteristics and prognostic factors associated 
with ankle arthritis in children with JIA. The ankle joint is described as the second most 
frequently involved joint, after the knee, and is estimated to affect 21-60% of children with 
JIA 32, 65-68. In recent reports, foot-related disability has been associated with increased 
disease activity 69, and the need for improved foot care programs has been highlighted 69, 70. 
Furthermore, occurrence of ankle arthritis has been associated with more progressive 
disease 65, 68, 71, 72 and with reduced physical activity, as assessed by accelerometry 73. The 
ankle and the elbow joints have also been shown to be more prone to ultrasound verified 
subclinical activity in patients in remission 74, 75. However, the designs of existing studies 
reduce generalizability of the result. Therefore the occurrence, clinical characteristics and 
prognostic factors associated with ankle arthritis were evaluated in a prospective, 
longitudinal and population-based cohort including 440 children with JIA (Study III). 
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Table I. Adopted from ILAR classification criteria, definitions and exclusions 34.                                    
 
Systemic Arthritis 
Definition: Arthritis in one or more joints with or 
preceded by fever of at least 2 weeks’ duration 
that is documented to be daily (“quotidian”) for 
at least 3 days, and accompanied by one or 
more of the following: 
1. Evanescent (nonfixed) erythematous rash 
2. Generalized lymph node enlargement 
3. Hepatomegaly and/or splenomegaly 
4. Serositis 
Exclusions: a, b, c, d. 
 
Oligoarthritis 
Definition: Arthritis affecting one to 4 joints 
during the first 6 months of disease. Two 
subcategories are recognized: 1. Persistent 
oligoarthritis: Affecting not more than 4 joints 
throughout the disease course 
2. Extended oligoarthritis: Affecting a total of 
more than 4 joints after the first 6 months of 
disease 
Exclusions: a, b, c, d, e. 
 
Polyarthritis (Rheumatoid Factor Negative) 
Definition: Arthritis affecting 5 or more joints 
during the first 6 months of disease; a test for 
RF is negative. 
Exclusions: a, b, c, d, e. 
 
Polyarthritis (Rheumatoid Factor Positive) 
Definition: Arthritis affecting 5 or more joints 
during the first 6 months of disease; 2 or more 
tests for RF at least 3 months apart during the 
first 6 months of disease are positive 
Exclusions: a, b, c, e. 
 
Psoriatic Arthritis 
Definition: Arthritis and psoriasis, or arthritis 
and at least 2 of the following: 
1. Dactylitis 
2. Nail pitting or onycholysis 
3. Psoriasis in a first degree relative 
Exclusions: b, c, d, e. 
 
Enthesitis Related Arthritis 
Definition: Arthritis and enthesitis, or arthritis or 
enthesitis with at least 2 of the following: 
1. The presence of or a history of sacroiliac joint 
tenderness and/or inflammatory lumbosacral 
pain 
2. The presence of HLA-B27 antigen 
3. Onset of arthritis in a male over 6 years of age 
4. Acute (symptomatic) anterior uveitis 5. 
History of ankylosing spondylitis, enthesitis 
related arthritis, sacroiliitis with inflammatory 
bowel disease, Reiter’s syndrome, or acute 
anterior uveitis in a first-degree relative 
Exclusions: a, d, e. 
 
Undifferentiated Arthritis 
Definition: Arthritis that fulfills criteria in no 
category or in 2 or more of the above categories
 
 
Exclusions a: Psoriasis or a history of psoriasis in the patient or first degree relative. b: Arthritis in an 
HLA-B27 positive male beginning after the 6th birthday. c: Ankylosing spondylitis, enthesitis related 
arthritis, sacroilitis with inflammatory bowel disease, Reiter’s syndrome, or acute anterior uveitis, or 
a history of one of these disorders in a first-degree relative. d: The presence of IgM rheumatoid 
factor on at least 2 occasions at least 3 months apart. e: The presence of systemic JIA in the patient. 
Abbreviations: ILAR, International League of Associations for Rheumatology. 
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1.2.2 Rheumatoid Arthritis 
RA is a chronic, inflammatory, autoimmune, systemic disease and is the most common 
rheumatic disease in adults. The etiology of RA is unknown but both genetic and 
environmental factors are thought to contribute to disease onset 76. Population based 
studies demonstrate that RA affects about 0.5-1 % of the general population in developed 
countries 77 and in Sweden 0.5-0.7 % 78. The peak age of onset is between 55 and 60 years 79 
and women are affected to a larger extent with a gender ratio of 3:1 77, 80. In 2010 a new 
classification criterion was established in order to optimize diagnosis 81. In this thesis adults 
with RA were, however, diagnosed using the ACR criterion from 1987 (Table II) 35. 
 
 
Table II.  Adopted from the 1987 ACR classification criteria for RA 35 
Criterion Definition 
Morning stiffness  Morning stiffness in and around the joints, lasting at least one hour 
before maximal improvement. 
Arthritis in at least three joints At least three joint areas simultaneously have had soft tissue swelling 
or fluid (not bony overgrowth alone) observed by a physician. The 14 
possible areas are right or left proximal interphalangeal (PIP), 
metacarpophalangeal (MCP), wrist, elbow, knee, ankle, and 
metatarsophalangeal (MTP) joints. 
Arthritis in hand joints At least one area swollen (as defined above) in a wrist, MCP, or PIP 
joint. 
Symmetric arthritis Simultaneous involvement of the same joint areas (as defined in 2) on 
both sides of the body (bilateral involvement of PIPS, MCPs, or MTPs is 
acceptable without absolute symmetry) 
Rheumatoid nodules Subcutaneous nodules, over bony prominences, extensor surfaces, or 
in juxta-articular regions, observed by a physician 
Rheumatoid Factor (RF) Demonstration of abnormal serum of rheumatoid factor by any 
method for which the result has been positive in less than 5% of 
normal control subjects.  
Radiographic changes Radiographic changes typical of RA on posteroanterior hand and wrist 
radiographs, which must include erosions or unequivocal bony 
decalcification localized in or most marked adjacent to the involved 
joints (osteoarthritis changes alone do not qualify) 
4/7 variables need to be fulfilled for classification as RA. Criteria 1 through 4 must have been present 
for at least 6 weeks. Abbreviations: RA, Rheumatoid arthritis; ACR, American College of 
Rheumatology 
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1.3 TREATMENT MANAGEMENT 
Treatment management in individuals with RA and JIA is based on a combination of 
pharmacological therapy, physical and occupational therapy, and psychosocial support, 
often provided by an inter-professional rheumatology team.  
Pharmacological treatment  
The primary focus of pharmacological therapy is the prompt resolution of inflammation in 
order to prevent joint destruction and systemic disease effects, to reduce disability and to 
improve health-related quality of life 82, 83. Presently, there is no treatment that cures 
arthritis; still, recent advances in pharmacological treatment have changed the expectations 
of treatment over time, with sustained remission as the paramount goal 82, 83. Nowadays a 
wide range of effective medication is available ranging from Non-Steroidal Anti-
Inflammatory (NSAID) drugs and steroidal Intra-Articular corticosteroid injections (IACI) to 
Disease-Modifying Anti-Rheumatic Drugs (DMARDS) like methotrexate, and biological 
agents directed towards specific disease modulators, such as  anti-Tumor Necrosis Factor-
alpha (TNF-α) 84. Both in children with JIA and in adults with RA there is evidence of a 
window of opportunity during which early pharmacological treatment can change the 
disease course in a milder direction and diminish destruction and deformity of the joints 85, 
86.   
TNF is a cytokine that plays a key role in the inflammatory and immune responses. 
Treatment with anti-TNF-α aims to reduce disease activity and joint damage progression 31, 
87. Symptom relieving effects appear rapidly, often within days or weeks and produce both a 
local effect on inflammatory joint symptoms as well as a global effect on pain, stiffness and 
well-being. Multiple studies have evaluated the effect of anti-TNF-α treatment on disease 
activity in adults with RA and, with some variation in estimates, about 40% of patients have 
a good effect, 30% have a moderate effect and 30% have little or no effect 31.  Anti-TNF-α 
treatment has a positive effect on the degenerative process particularly when combined 
with DMARDS such as methotrexate 31. 
IACIs are an important therapeutic option to relieve the symptoms of active synovitis 88-91 
even though the effectiveness in joints in the lower extremities has been discussed 92. The 
symptom relieving effect appears rapidly with most effects during the first three weeks. This 
mode of therapy is generally considered for treatment in individuals with arthritis in a small 
number of joints, particularly large joints, or with a polyarticular disease with the aim of 
inducing prompt remission of synovitis, while simultaneously continuing/initiating therapy 
with DMARDs and/or biologic agents. IACI also plays an important role in the prevention of 
deformities 91. In children with JIA, ankle arthritis has proven to be more resistant to 
treatment with IACI than the knee, with relapse occurring in 55% of ankle vs. 27% of knee 
joints 93, and the risk of relapse has been estimated higher in the ankle and subtalar joints 
than in other joints, e.g. knee and wrist 89, 90.  
Non pharmacological treatment 
Physical inactivity remains common in both adults with RA 94 and children with JIA 95, 96 
despite numerous studies having shown positive effects of physical activity on disease 
activity 97. Maintenance of an active lifestyle is vital for individuals with inflammatory joint 
disease, both to reduce the impact of arthritis-associated comorbidities 98, 99 and to benefit 
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from the positive effects of physical activity on general health and fitness 2, 98, 99. Thus, the 
main goals for physical therapy interventions are to facilitate physical activity and to reduce 
the impact of disease by encouraging individuals to regularly undertake in exercises to 
improve or maintain: joint motion, balance, coordination, cardiovascular fitness and 
muscular strength. To gain benefits for general health and fitness, general 
recommendations by the World Health Organization (WHO) were stated for both adults and 
children 6. The recommendations for physical activity for individuals with rheumatic disease 
are the same as for healthy individuals. However, the level and choice of activity needs to be 
carefully adapted to the individual’s capacity, disease severity, and fluctuations of the 
disease 100. To gain health benefits, moderate and high intensity activities are 
recommended; however, walking is an important component of total physical activity and is 
an accessible and low-cost way of being physically active. 
1.4 MEASURING GAIT DYNAMICS 
Walking has long fascinated humans, and documentation on the subject exists from the 
time of Aristoteles, 384-322 BC. In the middle of the 19th century, along with the advances 
in photography, the first scientific attempts to understand walking took place. An increase in 
interest in instrumental clinical gait analysis followed at the beginning of the 20th century, 
with the need to rehabilitate adults returning from war with amputations. But the real 
breakthrough came with the invention of powerful computers in the 1980s 101.  Walking is a 
fundamental function and the most natural and convenient way of moving short distances, 
and often, only requiring a pair of comfortable shoes.  
In clinical settings, walking function is commonly measured using walking speed 17, the six-
minute walk test 102, or self-reported questionnaires, such as the Health Assessment 
Questionnaire (HAQ) 103, Child HAQ (CHAQ) 104 and Rheumatoid Arthritis Quality of Life Scale 
105. Performance based measures, such as the timed up-and-go and the six-minute walk test, 
etc., are useful to quantify functional improvements or to classify function in a clinical 
setting but are not informative about movement quality. Performance based tests are 
informative in determining if walking function is impaired and by how much (in seconds or 
distance), but are not helpful in answering questions about the “which and why” of 
abnormal walking patterns. Both inflammatory and mechanical processes contribute to the 
development of pain and deformities and eventually disability in individuals with arthritis 16.  
In order to enhance the understanding of how these processes impact gait dynamics the 
combination of advanced measures such as three dimensional (3D) gait analysis and ultra 
sound (US) has been recommended 12, 106. 
1.4.1 Three dimensional gait analysis 
3D gait analysis provides detailed information about normal and pathological gait and is 
useful in clinical practice and for research purposes 101. Information about joint rotation and 
forces are obtained to further outline the relationship between joint disease, joint 
impairments and compensatory gait strategies 16. The predominant focus in studies using 3D 
gait analysis in adults with RA has been on the foot, with fewer studies examining the 
influence of the larger joints in the lower extremities 17, 18. This is reasonable since the foot 
and ankle complex is highly involved in the disease process, both in adults with RA and 
children with JIA 67, 107. A few studies have evaluated gait in children with JIA 10, 20, 21, 108-112. 
Most studies including 3D gait analysis in RA and JIA are observational or evaluate 
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orthopedic interventions 18, 20, 21 and, as previously discussed, there are only few studies 
evaluating the effect of pharmacological intervention on gait dynamics. 
A motion analysis laboratory contains specialized equipment operated by a team of 
multidisciplinary personnel, including physiotherapists, podiatrists, engineers and medical 
doctors such as orthopedic surgeons, neurologists and rheumatologists 101. Motion analysis 
begins with physical examination including assessments of joint range of motion, muscular 
contracture, muscle strength, bony deformity and examination of the neurological system. 
Gait analysis can be performed either barefoot or with footwear and with or without 
walking aids. During 3D gait analysis an individual is instructed to walk back and forth on an 
established pathway, approximately 10 meters in length, while measures of kinematics and 
kinetics are obtained using 3-D cameras and force-plates 114. 
 
Areas of potential use for  3D gait analysis within rheumatology 
 Explain the relationship between joint disease, joint impairments, compensatory 
gait strategies and walking disability 
 Establish as a baseline before treatment 
 Evaluate interventions e.g. pharmacological, surgical and conservative (orthotics, 
and physiotherapy) 
 Patient educational purposes 
 Complement information obtained through self-reported and performance 
based outcomes 
 
 
From 3D gait analysis, measures of kinematics, kinetics and spatiotemporal parameters can 
be obtained to enhance our understanding of specific gait pathology 18. Kinematics is 
defined as bone motion or the relative motion between two adjacent bones, but does not 
account for the cause of that motion. Thus, kinematics includes joint rotations, velocities 
and acceleration and answer questions about which gait deviations are occurring. Kinetics 
includes the study of forces, moments and powers and may answer questions about why a 
specific gait deviation occurs 101, 114. These forces, not visible to the eye, are measured 
through the use of force plates. A movement of the body can be generated by moments. 
Moments are the effect of a force acting at a distance from the joint axis, and may cause the 
segment to rotate or to stop rotating. Moments are described either as internal (the forces 
from muscles, ligaments and tendons that act on a joint) or external (gravitational, inertial, 
and contact forces acting on the body) 101, 114. Joint power provides information regarding 
muscle action, such as whether the muscles are performing eccentric or concentric 
contractions and is estimated by multiplying the joint moments and angular velocity. Joint 
powers are classified as either absorbing power (eccentric contraction) or generating power 
(concentric contraction) 101, 114. Simultaneously during the 3D gait analysis, information 
about spatiotemporal parameters, e.g. walking speed, stride length, step length and limb 
support time can be obtained. These measures are important, not only to provide a 
description of an individual’s walking function but also to interpret measures of kinematics 
and kinetics 115. Moreover, spatiotemporal parameters are commonly normalized to height, 
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and moment and powers to body weight, in order to allow comparisons between individuals 
and over time 116.  
A standardized terminology is adopted to analyze gait dynamics. Analyses are based on a 
gait cycle, also referred to as a stride, which starts when the foot strikes the ground and 
ends when the same foot strikes the ground again. A gait cycle is subdivided into a stance 
phase, the first 60% and a swing phase, the last 40% of the gait cycle. The stance and swing 
phases are further subdivided to enhance communication and understanding of gait 
deviations 101.  
Measures of gait dynamics 
Gait variables obtained with 3D gait analysis are often reported as single values, such as 
minima or maxima, or ranges of motion, e.g. max knee flexion in swing or max dorsiflexion 
in stance 11. However, interpretation of an individual’s level of overall gait quality may be 
difficult due to the complexity and interdependence of gait data and the volume of variables 
generated. During the last decade, several statistical methods, indexes and classifications 
based on data from 3D gait analysis were developed in order to create scores indicating 
overall gait quality, well summarized by Cimolin & Galli (2014) 117. In this thesis only the Gait 
Deviation Index (GDI) published in 2008, and the GDI- kinetic from 2011 are considered 118, 
119. The GDI scores are generic, thus they quantify gait deviations in any individual and 
generate a unique score for the left and right sides. The GDI is a measure of overall gait 
quality and is informative of the level of deviance in an individual’s gait pattern compared to 
the average gait pattern of heathy controls. Thus, the GDI score itself is not informative of 
which joint rotations or anatomical planes are most effected. The GDI is based on 
kinematics from the pelvis and hip in all three anatomical planes, the knee and ankle in the 
sagittal plane and foot progression in the transversal plane 119 and the GDI-kinetic includes 
frontal and sagittal plane moments and joint powers from the hip, knee and ankles 118. A 
GDI score of 100 or higher indicates typical gait pattern, while each 10 point decrement 
below 100 indicates 1 SD from normal gait, e.g. a GDI score of 89 indicates 1.1 SD from 
normal gait. GDI scores incorporate the entire variability across the gait cycle and take both 
deviations in timing and amplitude into account.  
Using the GDI as a measure of overall gait quality in individuals with RA and JIA was novel 
with Studies I, II and IV. The GDI is used for populations with cerebral palsy to improve the 
understanding of the overall gait deviations, and to follow individuals over time or after 
interventions 119-124. We believe this could also be true within rheumatology and doing so 
would enhance the understanding of the relationship between mechanical and 
inflammatory processes and gait deviations, and their interplay over time and following 
interventions. Moreover, relating measures of gait quality to measures of walking disability 
would add to the understanding of the association between them.  
Reduced walking speed and cadence, shorter stride and step length, and prolonged double 
limb support time are common findings in individuals with RA and JIA 18, 21. In healthy 
individuals reduced walking speed has been linked to reduced movements and moments 115, 
not unlike the specific gait patterns noted in RA and JIA 11. Thus, a current debate focuses on 
whether speed or pathology, or a combination of both, are the main cause of gait deviations 
13, 125, 126. A combination is most likely the cause, however, the impact of walking speed on 
gait dynamics varies with the actual speed and pathologies involved.   
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Joint power is informative of the type of muscle contraction and the rate at which the 
muscles are contracting. Adequate ability to generate and absorb joint power is necessary 
for activities of daily living such as walking and stair-climbing. Joint power can be 
compromised for many reasons such as reduced speed, reduced range of motion, stiffness 
and muscular weakness 127. In healthy individuals, the ability to generate power in both the 
ankle and the hip has been identified as an important factor in increasing walking speed 128. 
In older healthy adults and in individuals with neurological disabilities a distal-to-proximal 
shift in muscle function has been demonstrated when ankle power has been impaired 157, 
158. In Study IV in this thesis, the ability to generate ankle and hip joint power was evaluated 
after treatment with foot IACI in children with JIA. Since ankle arthritis has been associated 
with reduced muscular strength, we hypothesized that ankle power would be impaired in 
relation to healthy controls 55. Furthermore we hypothesized that the ability to generate 
ankle power would improve with treatment. 
1.5 RATIONALE FOR THIS THESIS 
Gait deviations in individuals with RA and JIA have previously been demonstrated as a 
consequence of active disease. Within the current era of new and potent medications, it is 
important to determine whether gait dynamics are impaired despite pharmacological 
interventions. It is also important to identify usable measures of overall gait quality that 
facilitate comparisons between groups and following interventions, in order to enable 
future longitudinal analyses. The studies in this thesis extend the knowledge and 
understanding of changes in gait dynamics following pharmacological interventions in 
individuals with RA and JIA. Moreover, the implication of ankle arthritis on disease 
progression and on gait dynamics is demonstrated and discussed. The findings from this 
thesis could, together with future research in this field, make important contributions to 
improving clinical guidelines and treatment recommendations for improved walking ability 
in individuals with RA and JIA 
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1.6 AIMS 
The aims of this thesis were to evaluate the usability of measures of overall gait quality and 
the effect of pharmacological interventions on gait dynamics in individuals with RA and JIA.  
The specific aims of the studies were: 
Study I 
To evaluate the usability of the GDI in adults with RA. The specific aims were: a) to evaluate 
the ability of the GDI to identify gait deviations b) to evaluate the inter-trial repeatability 
and c) to examine the relationship between GDI and walking speed, physical disability and 
pain.  
 
Study II 
To determine the effects of anti-TNF-α treatment on gait dynamics in adults with RA. 
Study III 
To evaluate the occurrence, clinical characteristics and prognostic factors associated with 
ankle arthritis in children with JIA. The specific aims were: a) to describe clinical 
characteristics in children with early ankle arthritis and b) to assess associations between 
early ankle arthritis and disease progression and remission status eight years after disease 
onset. 
Study IV 
To evaluate short (3 weeks) and long-term (3 months) effects of IACI treatment on overall 
gait dynamics and patient-relevant outcomes in children with JIA who had foot and ankle 
arthritis. The specific aims of this study were: a) to evaluate gait dynamics and self-reported 
physical disability before and following treatment with IACI and b) to determine whether 
children with polyarthritis and oligoarthritis respond similarly to IACI treatment. 
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2 METHODS 
Several outcome measures were used in the four studies (Table III). A brief summary of the 
study outlines are presented below, followed by a more detailed description in tables and 
text regarding participants, data collection, evaluation methods, and data analysis. 
2.1 STUDY OUTLINES 
Study I 
A retrospective case-control analysis was performed to evaluate the usability of the GDI in 
adults with RA. Sixty-three adults with RA and 59 healthy controls without walking 
difficulties participated in the study. All subjects with RA who had performed a gait analysis 
at the Motion Analysis Laboratory at the Karolinska Hospital, Stockholm between 2002 and 
2010 were considered for inclusion. Included data were obtained at gait analysis, from the 
Swedish Rheumatology Quality Register 130 or from the patient’s medical record. 
Study II 
A prospective pre-post design study was conducted to quantify the impact of anti-TNF-α 
treatment on gait dynamics in adults with RA. Sixteen adults with RA who started treatment 
with anti-TNF-α between 2004 and 2010 were included. Gait dynamics, pain, disease activity 
and self-reported physical disability were evaluated before introduction of anti-TNF-α 
treatment and after three months of treatment. 
Study III 
The occurrence of ankle arthritis and associations with polyarticular disease and failure to 
achieve remission was assessed in a prospective population based cohort study. Four 
hundred forty children with JIA, including all ILAR categories, from four Nordic countries 
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were included over an eight year interval. Relevant data was retrieved from the Nordic 
Study group of Pediatric Rheumatology (NoSPeR) database.  
Study IV 
A prospective pre-post design study was conducted to evaluate the effect of foot IACI on 
gait dynamics using 3D gait analysis and clinical outcome measures. Forty-three children 
with JIA undergoing treatment with IACI due to foot synovitis between 2008 and 2013 were 
included together with 40 healthy controls matched by age and gender. Gait dynamics, pain 
and foot-related disability were evaluated before treatment, and three weeks and three 
months after treatment. 
 
Table III. Overview of design, participation, outcome measures and data analysis in the thesis. 
Study Design Participants Outcome measures Data analysis 
I Retrospective, 
cross-sectional, 
case-control 
study 
n= 122 
63 adults with RA 
59 healthy adults 
 
Gait dynamics 
Pain 
Physical disability 
 
Descriptive statistics 
ICC 2.1 
One-way ANOVA 
Student´s t-test 
II Prospective 
pre-post design 
study 
n=16  
adults with RA 
Gait dynamics 
Pain 
Physical disability 
Disease characteristics 
Descriptive statistics 
Sample size calculation 
Spearman´s rank correlations 
Wilcoxon´s signed rank test 
III Prospective 
population 
based cohort 
study 
n=440 
children with JIA, 
all ILAR categories 
Ankle arthritis 
Pain 
Physical disability 
Disease characteristics  
Descriptive statistics 
Chi-square (χ2) 
Logistic regression 
Mann Whitney U test 
IV Prospective pre-
post design 
study 
n=83 
43 children with JIA 
40 healthy children 
Gait dynamics 
Pain 
Physical disability 
Foot-related disability 
Disease characteristics 
Descriptive statistics 
Friedman´s Two-Way ANOVA 
Linear mixed model 
Student´s t-test 
Wilcoxon´s signed rank test 
Abbreviations: RA, Rheumatoid Arthritis; JIA, Juvenile Idiopathic Arthritis; ILAR, International League 
of Associations for Rheumatology; ICC, Intraclass Correlation Coefficient; ANOVA, Analysis of 
Variance 
 
2.2 PARTICIPANTS AND DATA COLLECTION 
A total sample of 645 individuals participated in the present thesis. Two studies (Study I and 
II) included adults and two studies (Study III and IV) included children. The pre-treatment 
gait analysis evaluation for participants in Study II was included in Study I. Healthy 
participants were included in Study I and IV (n=99, Study I: 59 adults and Study IV: 40 
children) (Table IV). In this thesis, healthy participants are defined as individuals without any 
condition known to affect walking function such as: musculoskeletal disease, inflammatory 
joint disorder, neurological disorder, or gross motor delay. 
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Table IV. Overview of participants in Studies I-IV. Details of participants characteristics are described 
in each paper. 
Study Participants 
Gender 
(number 
female/male) 
Age at inclusion 
(years min-max) 
Disease 
duration 
(years min-max) 
I 63 adults with RA 54/9 25-82 1-46 
 59 healthy adults 38/21 25-86 n.a 
II 16 adults with RA  
(overlapping with Study I) 
11/5 35-74 1-39 
III 440 children with JIA 291/149 1-16* n.a 
IV 43 children with JIA 35/8 5-18 0.5-14 
 40 healthy children 28/12 5-20 n.a 
Abbreviations: RA, Rheumatoid Arthritis; JIA, Juvenile Idiopathic Arthritis; n.a, not applicable. * Age 
at disease onset. 
 
Study I 
In Study I, 63 adults with physician-diagnosed RA, and 59 healthy adults, matched by age, 
were included from the Motion Analysis Laboratory database at the Karolinska University 
Hospital, Stockholm. Participants had completed a 3D gait analysis between 2002 and 2010 
11, 129. All individuals with RA fulfilled the 1987 revised ACR criterion 35, had lower extremity 
involvement, and did not use walking aids. Exclusion criteria were: a history of major joint 
surgery, such as total joint arthroplasty or arthrodesis of the hip, knee, or ankle, or IACI less 
than four weeks prior to examination. Individuals with a neurological disorder or gross 
motor delay were excluded, as were those with a HAQ score registered more than one 
month from the date of the gait analysis. Of the 86 patients identified in our database with 
inflammatory joint disease, 23 did not meet the inclusion criteria or met the exclusion 
criteria, yielding a cohort of 63 participants.  
Data from one gait analysis session for each included individual were used in the analysis. If 
individuals with RA had done multiple gait analysis evaluations, the first analysis was used. 
Measures of demographics, medical treatment, physical disability, and pain were obtained 
either at the gait analysis session, from the patient´s records or from the Swedish 
Rheumatology Quality Register 130, a national database of health information. Data 
registered within one month of the gait analysis session were included. Two clinical 
researchers (ACE, EWB), experienced in gait analysis, collected the data using a standardized 
procedure. 
Study II 
Sixteen adults with RA were included. Patients were recruited between 2004 and 2010 from 
the rheumatology outpatient clinic at Karolinska University Hospital, Stockholm and from 
one private rheumatology outpatient clinic in Stockholm. All patients were selected on the 
basis of availability and willingness to participate and were scheduled to start anti-TNF-α 
treatment, either of Etanercept (38%), Infliximab (31%), Adalimumab (25%) or Golimumab 
(6%). To be included in the study, participants had to meet the following criteria: (i) 
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physician-confirmed RA, meeting the 1987 ACR criterion for RA 35,  (ii) lower extremity 
involvement but no use of walking aids, (iii) initiation of treatment with anti-TNF-α after 
performing the gait analysis, (iv) no history of joint surgery (arthroplasty and/or arthrodesis 
of the hip/ knee and/or ankle), and (v) no intra-articular steroid injections within four weeks 
before the gait analysis. Eighteen patients were included but two patients were excluded 
from the analysis because of technical data acquisition issues.  
Participants conducted two 3D gait analyses, one prior to the start of their anti-TNF-α 
treatment and one after three months of treatment. The analyses were conducted by either 
of two investigators (EWB, ACE). GDI and GDI-kinetic scores were calculated based on data 
from the 3D gait analysis 118, 119. Measures of pain, physical disability and disease activity 
were collected at baseline and at the 3-months follow-up, either at the gait analysis session 
or retrieved from the Swedish Rheumatology Quality Register 130.  
Study III 
The population-based approach Nordic JIA cohort consists of 500 children; among these, 
440 were followed prospectively for a median of 97 months (IQR 95–105) and classified 
according to the ILAR criteria. Consecutive incident cases of newly diagnosed JIA from 
defined geographic areas of Denmark, Finland, Norway and Sweden were included. The 
inclusion period was from January 1 1997 to June 30 2000 (3.5 yrs. in Norway, 3.0 yrs. in 
Sweden, Finland and Copenhagen, Denmark and for 1.5 yrs. in Århus, Denmark). During the 
study period, pediatric rheumatologists from twelve participating centers registered all 
children with JIA.  ILAR category was determined for the majority of patients, separately by 
two of the authors (LB and EN), and based on all available information that was registered at 
each visit during the study period 34. The study design and disease characteristics of the 
participants are extensively described elsewhere 131.  
Data included in Study III were retrieved from the Nordic JIA cohort database by two 
researchers (LB, ACE). Number of active joints in the lower extremity over the first eight 
years of disease was analyzed in relation to data of disease characteristics, level of physical 
disability and disease outcome.  
Study IV 
Forty-three children diagnosed with JIA, according to the ILAR criteria 34, and 40 healthy 
children matched by age participated in the study. Children with JIA were included 
consecutively between October 2008 and January 2011 and between November 2011 and 
March, 2013 from the Astrid Lindgrens Children’s Hospital. Inclusion criteria were: i) active 
arthritis in any foot joint ii) scheduled for IACI iii) aged between 5 and 18 years, iv) typically 
developing otherwise and v) able to understand written and spoken Swedish. Additional 
joint injections in knees, hips and upper extremities were allowed. Exclusion criteria 
included IACI less than four weeks prior to the assessment and any history of major surgery 
in lower extremity such as ankle arthrodesis. Children were placed under general anesthesia 
and injected in subtalar and midtarsal joints using fluoroscopy and contrast (Omnipaqe 300 
TM) to ensure an optimal needle placement and treatment effect. Triamcinolone 
hexacetonide (Lederspan®) was used in all joints except for distal and proximal phalangeal 
joints which were injected with methylprednisolone (Depo-Medrol®). Participants were 
instructed not to walk on the treated side/s for 24 hrs in accordance with the standard clinic 
protocol. 
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Gait dynamics, physical disability and disease characteristics in children with JIA were 
evaluated at three time points (Figure 3): prior to IACI treatment (mean (SD) = 5(7) days), 
three weeks after treatment (mean (SD) = 22(6) days) and three months (mean (SD) = 96(10) 
days) after treatment with IACI.  Two clinical researchers (SH, ACE) experienced in childhood 
rheumatic disorders extracted demographic and medical data from the patient’s medical 
record according to a standardized procedure to reduce the potential for misclassification 
bias. The following measures were collected: demographics, treated joints and baseline 
medications, joint impairments, pain, self-reported foot-related disability and gait dynamics. 
 
 
 
 
Figure 3. Overview of included children; study design and methods in Study IV. Note that 
three of the five children not participating in the 3 weeks evaluation did participate in the 
three months evaluation. 
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2.3 EVALUATION METHODS AND OUTCOMES 
Methods for data collection are summarized in Table V and described in details in the 
following section. 
 
Table V. Objectives and methods categorized according to the ICF structure 
Objective Method Study ICF 
Gait dynamics 3D Gait analysis I, II, IV Body function 
Pain VAS I, II, IV Body function 
  Faces pain scale   Body function 
Physical disability 
 
CHAQ/HAQ 
 
I-IV 
 
Activity &  
Participation 
Foot-related disability JAFI IV Body function      
Activity &  
Participation 
Disease characteristics 28- joint count, occurrence of 
arthritis, Joint Score 
II-IV 
Body function/ 
structure 
 
  DAS28-CRP, ESR, CRP,  II, III 
  ANA, HLA-B27, Uveitis  
Abbreviations: ICF, International Classification of Functioning, Disability and Health; 3D, three 
dimensional; VAS, Visual Analog Scale; HAQ, Health Assessments Questionnaire; CHAQ, Child HAQ; 
DAS-28, Disease Activity Score; ESR, Erythrocyte sedimentation Rate; CRP, C-Reactive Protein; ANA, 
Anti-nuclear antibody; HLA-B27, Human leucocyte antigen B27 
 
2.3.1 Measuring gait dynamics 
Three dimensional gait analysis 
3D gait analysis was conducted to assess deviations in gait patterns. All 3D gait analyses 
were conducted at the Motion Analysis Laboratory at the Karolinska University Hospital, 
Stockholm between 2002 and 2013. In most cases gait analyses were conducted in the 
afternoon to avoid morning stiffness, though some individuals did not report morning 
stiffness and preferred to come in the morning. At all sessions participants walked barefoot 
and at a self-selected comfortable speed. 
An eight-camera motion analysis system with passive markers (Vicon MX40, Oxford, UK) 
was used to measure kinematics and two staggered force plates (Kistler Type 9281C, 
Winterthur, Switzerland) were used to simultaneously measure ground reaction forces.  
Joint reaction moments and powers were computed through inverse dynamics 114. All 
moments in this thesis are presented as internal moments. Subjects walked on a 10 meter 
walkway and repeated the task up to 15 times in an effort to acquire kinematic and kinetic 
data from at least five gait cycles on each side. Effort was made to direct the subjects to 
strike the force plates cleanly and consecutively. Of the available gait cycles, three 
representative cycles were chosen for left and right side (leg) individually. All subjects were 
tested using a full-body model (34 markers, 15 segments) marker set. Markers were placed 
by experienced physiotherapists (EWB and ACE) on well-defined anatomical landmarks 
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(Figure 4). The lower body was modeled as seven segments (pelvis, two thighs, two shanks 
and two feet) according to Vicon’s Plug-In-Gait model 132. Measurements from the upper 
body (trunk, head and arms) are not included in the present thesis. Pelvis angles in all planes 
and foot progression (transverse plane) angles are described in global coordinates whereas 
all other hip, knee and ankle angles are described relative to the proximal segment. Each 
foot was considered as one rigid body, articulating with the tibia in plantar/dorsiflexion. 
 
Figure 4. Marker placement during 3D gait analysis. 
 
Spatiotemporal parameters, such as walking speed, stride and step length, were normalized 
according to Hof 116 to generate dimensionless (nd), and thereby comparable, numbers.  In 
Study IV, joint power generation was defined as the joint moment multiplied by the joint 
angular velocity divided by body weight (W/kg) and was calculated in pre-swing/ early 
swing.  
Gait Deviation Index (GDI), GDI-kinetic and speed-matched GDI 
The Gait Deviation Index (GDI) is a measure of overall gait quality in the lower extremity and 
is based on kinematics from the pelvis and hip in all three anatomical planes, the knee and 
ankle in the sagittal plane and foot progression in the transversal plane 119 (Figure 5). The 
GDI-kinetic includes frontal and sagittal plane moments and joint powers from the hip, knee 
and ankles 118. Thus, GDI scores are based on gait parameters that can only be obtained by 
3D gait analysis. GDIs, both for the individuals with RA/ JIA and the healthy controls, were 
calculated using MATLAB 119 and the calculations were based on a reference set walking at a 
self-selected speed and consisted of one representative stride from right and left side in 83 
healthy children (Study I) 115, 59 healthy adults (Study II) and 40 healthy children (Study IV). 
GDI-kinetic scores in Study II were based on a reference set of 56 adults. Two GDI scores are 
generated from each stride, for left and right side (leg) independently. GDI scores are 
interpreted as follows: a value of 100 or higher indicates a typical gait pattern; while each 
10-point decrement below 100 indicates one standard deviation (SD) from typical gait (e.g. a 
GDI score of 85 indicates 1.5 SD from normal gait).  
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The process from 3D gait analysis to GDI scores 
 
 
 
 
 
 
 
A B 
Normal GDI interval 
100 (SD 10) 
C D 
GDI scores do not control for the effects of walking speed, thus healthy individuals walking 
at slower speeds have GDI scores of less than 100. To evaluate the effect of speed on the 
GDI in individuals with RA, GDI scores were additionally calculated using a speed-matched 
reference set (Study I) 133.  These speed-matched GDI scores (SMGDI) are described in detail 
in Study I 134. 
 
Figure 5. Reflective markers are placed on anatomical landmarks (A). Body parts are 
simplified to segments (B) and movements are displayed in three planes (C). Solid lines 
represent left side and dashed lines represent right side (C). The Gait Deviation Index (GDI) 
(D), a measure of overall gait quality, is based on 9 gait curves from 3 planes and 4 joints. A 
GDI score of 100 or higher indicates normal gait pattern, while each 10 point decrement 
below 100 indicates 1 SD from normal gait (e.g. GDI = 85 means 1.5 SD from normal gait). 
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2.3.2 Measuring pain 
Visual Analogue Scale and the Faces Pain Scale 
In Study I and II, a Visual Analog Scale (VAS) ranging from 0 (no pain) to 100 (worst pain) was 
used to assess pain during walking at the gait analysis session 135. In Study IV, the faces pain 
scale-revised was used for children younger than eight years of age 136. The faces pain scale 
uses six pictures to illustrate pain ranging from “no pain” to “worst pain” 137. The pain scales 
were rigorously explained using an interactive procedure. Directly after performing the 
walking task, the participants were asked to rate their perceived pain during walking as 
follows “Please rate how much pain you perceived during walking?” and “Where did it 
hurt?” In Study I, to assess the relationship between pain and gait dynamics, pain scores 
(VAS) were dichotomized into “no/low” pain (VAS 0 mm-30 mm) and “moderate/high” (VAS 
>30 mm) according to the proposed cut-point from Collins et al. 138.   
2.3.3 Measuring physical disability 
The (Child) Health Assessment Questionnaire disability index  
The Health Assessment Questionnaire disability index (HAQ) and the Child-HAQ (CHAQ) are 
20-item questionnaires providing information about self-assessed physical disability. They 
are shown to be valid and reliable tools for assessment in adults with RA and children with 
JIA 103, 104. Both HAQ and CHAQ contain eight domains addressing activities of daily living in 
the preceding week and include: walking, rising, hygiene, reach, dressing, handgrip eating 
and activities. Each item is scored on a four-point ordinal scale: 0 (without any difficulty), 1 
(with some difficulty), 2 (with much difficulty) and 3 (unable to do). The eight domains 
together make a disability index that is also complemented by two VAS scores, one for 
disease-related pain and one for disease-related overall well-being. In Study I, to study the 
relationship between physical disability and gait dynamics, HAQ scores were dichotomized 
into “no/low” physical disability (HAQ 0-1) and “moderate/high” (HAQ 1.1-3). In Study III, 
the rising, walking and activities domains were compiled into a disability index representing 
disability from the lower extremity by adding the scores from each domain and dividing by 
three. In Study IV the walking scale from the CHAQ (CHAQwalk) completed before injections 
was used to group children with JIA in three groups with: “no”, “some” and “much”  
reported walking disability. In Study III and IV a proxy version of the CHAQ was used for 
children under the age of nine and ten respectively. 
2.3.4 Measuring foot-related disability 
Juvenile Arthritis Foot disability Index 
The Juvenile Arthritis Foot disability Index (JAFI) was used to assess foot-related disability in 
the most involved foot over the preceding week (Study IV) 139. JAFI is a 27-question survey 
and is divided into three subscales: impairments (9 questions), activity (14 questions) and 
participation (4 questions). Each item is scored on a five-point ordinal scale: 0 (never), 1 
(occasionally), 2 (sometimes), 3 (frequently), and 4 (always). The JAFI has good content and 
construct validity and has demonstrated good reliability for assessing foot-related disability 
in children with JIA 139 and preliminary results indicate good responsiveness 140. Median 
score and minimum and maximum values are reported for each subscale individually. 
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2.3.5 Measuring disease characteristics 
Joint Score, 28-joint count and occurrence of arthritis 
Joint involvement was assessed differently in the studies comprising the thesis. In Study II, 
the number of swollen and tender joints was derived retrospectively from the Swedish 
Rheumatology Quality Register and based on a 28-joint count 141. In Study III, the cumulative 
number of joints with arthritis, as defined according to the ILAR criteria, was  totaled 34. In 
study IV, findings from clinical examination were compiled into a score called “ the Joint 
Score” 142. Hips, knees, ankles, hind/mid foot, and forefoot were assessed for: 1) capsular 
swelling or effusion (not for the hips or hind/mid foot), 2) tenderness and pain, and 3) loss 
of motion. A total score ranging from 0 (no impairment) to 26 (maximal impairment) was 
derived by adding the score from each joint 142. By using the “Joint Score” all the joints in the 
foot were included, which was not feasible with standard scores.  
Measures of disease activity and biomarkers 
In Study II, the 28-joint Disease Activity Score based on C-reactive protein (DAS28-CRP) 143, 
Erythrocyte Sedimentation Rate (ESR), and C-Reactive Protein (CRP) levels were analyzed 
before and three months after medical treatment. In Study III, the maximum values of ESR 
and CRP assessed during the first six months of disease were collected. 
In Study III, the following data were derived from the Nordic JIA cohort database and 
analyzed in relation to presence of ankle arthritis: remission status at the final visit as 
determined according to the preliminary criteria published by Wallace 144; uveitis, registered 
as present when confirmed by an ophthalmologist; Human Leukocyte Antigen B27 (HLA-
B27); AntiNuclear Antibody (ANA), performed twice, at least three months apart and 
cumulative numbers of affected joints. ANAs included in analysis were measured using 
immunofluorescence on HEp-2 cells and were interpreted as positive or negative according 
to the reference values used by the local laboratory in each country. 
2.4 STATISTICAL METHODS AND DATA ANALYSIS 
Statistical methods and data analyses used are presented in detail below. A summary of the 
statistical approaches can be found in Table VI. Statistical analyses were performed using 
Statistica Software 10.0 (StatSoft Inc., Tulsa, OK, USA) (Studies I and II), Statistical Package 
for Social Sciences (SPSS), version 22 (SPSS Inc., Chicago, IL, USA) (Studies III, IV), Statistical 
Analysis Software version 9.3 (SAS Institute Inc., Cary, NC, USA) (Study IV) or G*power 
3.1.9.2 (In Study II, sample size calculations) 145. Differences were considered statistically 
significant for p-values < 0.05. 
 Measures of kinematics, kinetics and spatiotemporal gait parameters obtained from 3D gait 
analyses were averaged over the three gait cycles per side to account for natural variation in 
gait pattern. In all analyses except for in the linear mixed model used in Study IV, kinematic, 
kinetic and spatiotemporal gait parameters were averaged over left and right sides and then 
used in statistical analysis. Statistical methods were chosen and analyses were performed 
based on type of data, e.g. categorical or interval data, data distribution and sample sizes. 
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Table VI. Overview of statistical methods used in Studies I-IV. 
Statistical method Study I Study II Study III Study IV 
Chi-square   X X 
Descriptive statistics X X X X 
Friedman´s two-way ANOVA    X 
Intra-class Correlation Coefficient (ICC2.1) X    
Linear mixed model    X 
Logistic regression   X  
Mann-Whitney U test   X  
One-way ANOVA X    
Sample size calculation  X   
Spearman´s rank correlation coefficient  X   
Student´s t-test X   X 
Wilcoxon´s signed rank test  X  X 
Abbreviations: ANOVA, Analysis of Variance 
 
Descriptive statistics (Study I-IV) 
Data types obtained in the different studies were ratio/interval, ordinal and categorical 
data. Ratio/interval data, e.g. gait analysis parameters, were presented using mean and 
standard deviation (SD) or median and minimum - maximum value or interquartile range 
(IQR, 25th to 75th percentile) depending on distribution of the data and the size of the 
sample. Ordinal data, e.g. from questionnaires, and VAS scales were presented by median 
and IQR or minimum and maximum values. Categorical data, e.g. presence of arthritis, were 
represented using total number and percent.  
Analysis of effect of pharmacological intervention 
In Study II, the effect of anti-TNF-α treatment on gait dynamics was assessed using 
Wilcoxon´s signed rank test due to skewed distribution and reduced sample size.  
Spearman’s rank correlation coefficient was used to evaluate if improvement following 
treatment was related to baseline values in GDI, GDI-Kinetic and spatiotemporal 
parameters. Improvement was calculated as a percentage as follows: (variable after anti-
TNF-α – variable before anti-TNF-α) / (variable before anti-TNF-α)*100. Correlations were 
interpreted according to Portney and Watkins: 0-0.25 (little or no relationship); 0.25–0.50 
(fair); 0.50–0.75 (moderate to good); and 0.75–1 (good to excellent) 146. 
Study IV: Effect of IACI treatment on VAS scores and Joint Score was estimated using a 
Friedman´s Two-Way Analysis of Variance (ANOVA) and on JAFI using Wilcoxon´s signed 
rank test. Differences gait dynamics over time in within children with JIA in relation to 
healthy children were calculated using a linear mixed model with two within effects; time, 
three time points (compound symmetry) and side left and right (unstructured).  
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Analysis of difference between individuals with JIA/RA and healthy 
controls 
In Study I, differences in demographic variables, GDI scores and spatiotemporal parameters 
between adults with RA and healthy adults were evaluated using a Student’s t-test. In Study 
IV, differences between the children with JIA and controls were estimated with a Chi-
squared test for the proportion females and males and with the Student´s t-test for age, 
weight and height. Differences in gait parameters between controls and children with JIA 
before treatment and three weeks after treatment were calculated using Student´s t-test. 
Differences between controls and polyarthritis and oligoarthritis respectively were analyzed 
with the Mann-Whitney U test due to skewed distribution and reduced sample size. 
Gait dynamics in relation to physical disability and pain 
In Study I, a one-way ANOVA was used to evaluate differences in GDI scores between 
individuals with RA when grouped according to level of physical disability (HAQ) and pain 
(VAS).  
Sample size recommendations 
In Study II, sample size recommendations for future studies were made based on the change 
in GDI, GDI-kinetic, dimensionless walking speed and stride length after anti-TNF-α 
treatment. In these calculations the following assumption was made: the differences 
following treatment could be considered a relevant difference between two different 
groups in a Randomized Control Study. The effect size was calculated by dividing the mean 
difference by the SD of difference for GDI, GDI-Kinetic, dimensionless walking speed, and 
stride length before and after anti-TNF-α treatment. Sample size calculations were based on 
an α-value of 0.05, a beta value of 0.8 and effect sizes.  
Reliability of the gait deviation index 
In Study I, the natural variation in GDI between strides at the same evaluation session the 
inter-trial (stride) repeatability was calculated with an Intra-class Correlation Coefficient 
(ICC2.1)
147, calculated from the mean square values derived from a one-way repeated-
measures ANOVA. Calculations were based on three strides, and for each stride left and 
right side were averaged. ICC2.1 was interpreted according to the recommendations of 
Landis and Koch 148. ICC gives no information about the size of disagreement between the 
included strides, and should be complemented by the Standard Error of Measurement 
(SEM). This was calculated by adding the variances between the repeated measures for each 
subject, dividing the sum of the variances by the number of the subjects (n), and taking the 
square root (√mean square-within targets). To determine the size of the variation in gait, the 
repeatability coefficient was calculated (SEM x 1.96 x √2) 149. However, the repeatability 
coefficient, also called the smallest detectable change (SDC) can be interpreted as “the 
magnitude of change below which there is more than a 95% chance that no real change has 
occurred” 150. The repeatability coefficient refers to individual levels and should not be used 
to interpret the average change for a group of individuals 149. 
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Analysis of impact of ankle arthritis  
In Study III, statistical analysis of differences in disease characteristics between children with 
and without ankle arthritis were estimated using Chi-square test (Fisher´s exact test 2-sided) 
for comparison of dichotomous variables and the Mann Whitney U test for comparison of 
non-parametric interval data. A multiple logistic regression analysis was performed in order 
to identify the association between early ankle arthritis and failure to achieve remission 
eight years after disease onset. The dichotomized variable remission (remission without 
medication) versus not being in remission (remission with medication and not in remission) 
was used as dependent variable in the regression model. The following independent 
variables were included; presence of ankle, knee and hip arthritis during the first year of 
disease, presence of HLA-B27, gender, and age at disease onset. A forward step-wise 
inclusion of variables was performed and the independent variables associated with the 
dependent variable (p<0.05 in the univariate analysis) were included in the multiple 
regression analysis. Results of the regression models are shown as odds ratio (OR) and 95% 
confidence interval (95% CI). The level of significance was set at 5% (p < 0.05). 
2.5 ETHICAL CONSIDERATIONS 
Studies I,II and IV were approved by the regional ethical board of Stockholm, Sweden. In 
Study III, The Research Ethical Committees in each country, Sweden, Norway, Finland and 
Denmark, gave their approval in accordance with national practice and legislation. All 
studies were conducted in accordance with the Declaration of Helsinki. Participation was 
voluntary and all participants were given oral and written information about the studies. 
Consent to participate in the study was obtained from all adults, and by parents or legal 
guardian where applicable in the pediatric population. 
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3 RESULTS AND DISCUSSION 
3.1 GENERAL 
In adults with RA the strongest predictor of walking disability eight years after disease onset 
is walking disability two years after disease onset 151. This result underpins the importance 
of identifying walking disability in early disease and revealing contributing factors. For 
example, there is evidence that gait deviations due to painful deformities in the foot may be 
improved by orthotic treatment when detected in early disease 152. Walking disability is 
complex, and in a study by van der Leeden et al. disease activity and pain were related to 
walking disability while joint deformities were not 151. Both disease activity and joint 
deformities have, however, been related to gait deviations 16. Within rheumatology the link 
between biomechanics of gait and walking disability has been identified as an important but 
under-researched area 16. The integration of biomechanics of gait into studies of patient 
subjective experience has the potential to yield new insights into factors contributing to 
walking disability 8. Within the current era of new and potent medications, it is important to 
ascertain whether gait dynamics are impaired despite pharmacological treatment. It is also 
important to identify usable measures of overall gait quality in order to facilitate 
comparisons between groups in future interventional or longitudinal analyses 18. 
The main findings in this thesis reveal that gait deviations persist despite pharmacological 
interventions. We suggest that the biomechanical perspective should be considered when 
evaluating walking disability in arthritis care. This can be facilitated by the use of measures 
of overall gait quality, such as the GDI. GDI scores add an aspect of dynamic function, 
facilitate longitudinal analysis and enable comparisons between groups or following 
interventions. Furthermore, ankle arthritis and foot-related disability are common in 
children with JIA and are related to failure to achieve remission. Based on these findings we 
suggest that ankle arthritis should be taken into consideration in the assessment of 
prognosis and choice of treatment strategy in JIA. 
In the following sections, main findings from the four studies in the thesis will be briefly 
presented and discussed followed by a discussion of methodologies and limitations. A 
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detailed description of results together with tables and figures are found in the original 
articles at the end of the thesis. 
3.2 RESULTS 
3.2.1 Ankle arthritis in JIA 
The occurrence, clinical characteristics and prognostic factors associated with ankle arthritis 
in children with JIA from the first eight years of disease were analyzed (Study III). This 
population-based cohort has the advantage of being representative of the whole disease 
spectrum and its diverse clinical phenotypes, facilitating generalizability of the results 131, 153. 
We hypothesized, and later concluded, that ankle arthritis was common and related to 
worse outcome. 
The ankle was the second most frequently involved joint and was involved in 57% of the 
children with JIA (Study III) (Figure 6).  The ankle presented early in the disease course with a 
median of seven months (IQR 6-13) after disease onset. Ankle arthritis was least common in 
the persistent oligoarticular category (25%) and most common in children with the 
extended oligoarticular (83%) and polyarticular RF negative disease (85%). The common 
occurrence of ankle arthritis must be seen in the light of existing literature pointing at 
diagnostic and treatment challenges, such as resistance to treatment with IACI 93, increased 
risk of relapse 89, 90, and subclinical activity 74, 75. Thus, it is important to diagnose ankle 
arthritis early in order to optimize treatment. 
 
 
 
Figure 6.  Arthritis in the lower extremity during the first eight years of disease (n=440, Study 
III) 
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In contrast to adult rheumatology, involvement of the ankle seemed to represent 
involvement of the whole foot 31. We found that in the 94 children with subtalar arthritis, 83 
(88%) had additional ankle arthritis and for the 75 children with tarsal involvement 81% had 
ankle arthritis. A similar pattern was seen between ankle joint and MetaTarsoPhalangeal 
(MTP) joints and toe arthritis (Study III).   
Children with occurrence of ankle arthritis during the first year of disease differed from 
those without early ankle arthritis in several aspects (Table VII). They were younger at 
disease onset and had higher levels of ESR and CRP during the first six months of disease 
after disease onset. Moreover, occurrence of ankle arthritis during the first year was 
associated with higher physical disability, with polyarticular disease course, and with failure 
to achieve remission eight years after disease onset. There was no difference between 
children with and without occurrence of early ankle arthritis during the first year regarding 
presence of ANA, HLA-B27 or uveitis.  
In a multiple regression model, occurrence of ankle arthritis within the first year of disease 
was associated with failure to achieve remission eight years after disease onset, OR 2.0 (95 
% CI 1.3-3.0) when adjustments were made for: knee and hip arthritis during the first year, 
age at disease onset, presence of HLA-B27 and gender. 
The common occurrence of ankle and foot arthritis in children with JIA reported from Study 
III is in conformity with existing research 33, 69-72. The strengths of our study were the 
population-based approach and the inclusion of all ILAR categories, which facilitate 
generalization of the results. The most important findings were probably the high frequency 
of ankle arthritis and the fact that early occurrence of ankle arthritis was associated with a 
polyarticular disease course in young children and with failure to achieve remission.  
Two clinical implications can be drawn from this study: first, an increased awareness of risk 
of extension to polyarticular disease course in children presenting with ankle arthritis and 
oligoarticular pattern; second, we suggest that occurrence of ankle arthritis should be taken 
into account in the assessment of prognosis and choice of treatment strategy in JIA. This 
could be achieved in clinical practice by including image-guided assessment, in order to 
detect arthritis extension early, as well as shorter follow-up intervals. 
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Table VII. Clinical characteristics for children with and without occurrence of ankle arthritis during first year of disease 
 
Total group 
Ankle arthritis 
first year of disease 
No ankle arthritis 
first year of disease 
Ankle vs. no 
ankle 
Characteristics  n                                                         n                                                             n                                                         p-value                      
Age at disease onset, median (IQR) 440 5.5 (2.5-9.7) 186 4.9 (2.1-8.8) 254 6.6 (2.8-10.1) 0.003b 
Gender, female n (%) 440 291 (66) 186 127 (68) 254 164 (65) 0.475a 
ANA positive, n (%) 391 107 (27) 160 46 (29) 231 61 (26) 0.645a 
HLA-B27 positive, n (%) 410 86 (21) 173 33(19) 237 53 (22) 0.462a 
        
Assessments, first six months of disease        
ESR mm/hour, median (IQR) 333 35 (16-55) 150 45 (26-77) 183 24 (12-48) <0.001b 
CRP mg/liter, median (IQR) 332 14 (0-35) 143 28 (10-56) 189 10 (0-23) <0.001b 
        
Assessments, first eight years of disease        
Cumulative joints, median (IQR)* 440  6 (2-12) 186 10 (6-16) 254 3 (2-9) <0.001b 
Remission at eight years follow-up, n (%) 427 181 (42) 183 63 (34) 244 118 (48) 0.004a 
Uveitis, n (%) 425 89 (21) 179 36 (20) 246 53 (22) 0.809a 
CHAQlow/HAQlow , n (%) >0 358 35 (10) 149 18 (12) 209 17 (8) 0.279
a 
CHAQ/HAQ, n (%) >0 359 110 (31) 149 56 (38) 210 54 (26) 0.020a 
aFisher’s exact test 2-sided, bMann-Whitney U test. n; number, ANA; Antinuclear antibody, HLA-B27; Human Leukocyte Antigen B27, (C)HAQ; (Child) Health 
Assessment Questionnaire. Values for the C-reactive protein (CRP) level and the erythrocyte sedimentation rate (ESR) are the maximum values reported 
during the first 6 months after disease onset, CHAQlow; Child Health Assessment Questionnaire lower extremity; percent of children rating > 0, indicating 
physical disability related to the lower extremities at the eight year follow-up. *Cumulative number of arthritis in specific joints that have been active during 
the first eight years of disease. 
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3.2.2 Measures of gait dynamics 
Gait deviation index scores 
While subjective evaluation of dynamic function after treatment in individuals with 
musculoskeletal disorders has been done for many years, valid objective measurements of 
dynamic function have been lacking. A novel aspect of this thesis was the use of the GDI 
scores, measures of overall gait quality, in individuals with RA and JIA. 
GDI scores add an aspect of movement quality during dynamic function and were shown to 
be useful facilitating comparisons between groups and following interventions (Study I, II 
and IV) (Figure 7). Individuals with RA and JIA show gait deviations as compared with healthy 
controls. Moreover, adults with RA (Study I and II) had more pronounced gait deviations 
than the children with JIA (Study IV) (Figure 7). The average GDI score for children with JIA 
was slightly lower compared to healthy controls but was not statistically different (Study IV). 
 
 
 
Figure 7. Overall lower extremity kinematics represented by GDI scores from Studies I, II and 
IV. * indicate level of statistical difference between groups. Using measures of gait quality 
facilitates comparisons between groups and after interventions. 
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The first discussions within our research group about developing a gait index for individuals 
with arthritis took place in 2008, the same year as the GDI was published 119. The GDI is, in 
contrast to its forerunners, a generic index and was proven valid to quantify gait deviations 
in any individual. Thus, we decided to evaluate the usability of the GDI as a measure of gait 
quality in adults with RA. The primary hypothesis was that the GDI would be a useful 
measure of overall gait quality within this group of patients.  
The results from Study I showed that gait deviations in adults with RA were evident and the 
mean GDI score was 87 (SD 9), which is about 1.3 SD below a GDI score of normal gait 
pattern (p< 0.001) (Figure 1, Study I). Among our sample many subjects had established 
disease, and did not have access to current medical therapy at disease onset. Thus, the gait 
deviations they exhibited may also reflect, apart from impairments due to arthritis, joint 
deformities and/or compensatory walking strategies adopted to avoid loading of painful 
joints 11. In the children with JIA in Study IV ,who had access to today´s more potent 
pharmacological treatment from disease onset, the level of gait deviation was minor with 
respect to kinematics (GDI score pretreatment 97 (SD 11) and did not differ statistically from 
healthy controls (Study IV). Moreover, this result could also be influenced by disease 
duration which was significantly shorter for children in Study IV (4.5 years (SD 3.6) compared 
to the participants with RA in Study I (15 years (SD 11). Another factor known to impact gait 
dynamics is pain 14, 17 but, interestingly; levels of pain were equivalent between the two 
samples.  
When using GDI scores in clinical and in research settings, it is useful to estimate how much 
difference is required for a meaningful clinical change. In Study I, the size of the natural 
variation in gait between strides assessed at the same session was estimated to be 5.4 GDI 
units. Thus, individual differences in GDI for a person with RA should be above five GDI units 
to account for natural variation in gait. Therefore we consider this the minimal change in 
GDI required to be clinically meaningful for an individual with RA. Importantly, this number 
should not be confused with Minimal Clinical Important Difference (MCID) which requires 
comparison with accepted clinical standard outcomes measuring walking function, and 
preferably includes the patient’s own perspective 154. Thus, the MCIDs for GDI in RA and JIA 
are still to be determined. Our result is based on a within-session analysis using several 
strides from one 3D gait analysis session per included individual (Study I). Variation due to 
marker placement, skin movement artifacts, time of the day, and the experience of the 
assessor/s was not taken into account 155. Subsequently, we would expect a greater 
difference from a between-session analysis.  
In conclusion, we recommend the use of GDI, or an equivalent measure, in future studies of 
gait dynamics in individuals with RA and JIA.  The GDI provides an overall impression of gait 
quality and may, in combination with other measures, help to understand the relationship 
between RA/JIA, gait deviations and walking disability. It was estimated that on an individual 
basis a change of five GDI units or more was required to account for the natural variation in 
gait. 
Walking speed  
Clinical impression and previous literature conclude that individuals with RA and JIA 
commonly walk with reduced walking speed and cadence, shorter stride and step length 
and prolonged double limb support time 18, 21. This was also true for the participants with 
arthritis included in this thesis (Study I, II, and IV). Walking speed is related to height, 
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meaning that tall people walk faster than people of short stature. Moreover, growing 
children may appear to walk faster over time but this may be an effect of skeletal growth 116. 
To overcome the problem with comparing walking speed in individuals of different height, 
spatiotemporal parameters obtained in this thesis were made dimensionless (normalized) 
according to the recommendations by Hof 116. Normalization of walking speed within 
rheumatology studies is uncommon and a detailed comparison with other studies is 
difficult. Individuals with RA and JIA included in this thesis (Study I, II and IV) walked with 
significantly reduced walking speed as compared to healthy controls (Figure 8). An 
important finding when comparing the walking speed from the RA and JIA populations in 
this thesis to healthy controls was that mean speed was still reasonably fast and, for most 
groups, within normal speeds of healthy controls 115 (Figure 8). We, and others, relate this 
positive result to today´s treatment paradigm resulting in reduced disease activity and joint 
destruction 112. 
 
 
 
 
Figure 8. Dimensionless self-selected walking speed summarized from Studies I, II and IV. 
Reference values on the x-axis are adopted from a reference set of 86 children walking at 
different speeds 115 and the vertical lines indicate different speed intervals. Free = self-
selected speed and at “slow” and “fast” speeds participants have been encouraged to slow 
or quicken their preferred walking velocity. * indicate level of statistical difference between 
groups. 
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Joint power 
In children with JIA ankle power was reduced as compared to healthy children both before 
and after foot IACI treatment, (p<0.001) (Figure 9) (Table 4 in Study IV). Adequate joint 
power is necessary for activities of daily living such as walking and stair-climbing. Joint 
power can be compromised due to reduced walking speed and reduced ranges of motion, 
both documented features in children with JIA (Table 4 in Study IV). It could also be possible 
that reduced generating ankle power is related to reduced muscle strength of the 
plantarflexors 55, 56, which is a common finding in clinical practice. McKay et al. (2013) 
evaluated the effect of knee IACI treatment on muscle strength and concluded that 
muscular weakness was related to factors other than active arthritis, including pain, muscle 
atrophy due to inactivity, as well as the effect of cytokines and inflammatory myopathy 56. 
Other possible causes of reduced ankle power during walking could be compensatory 
stiffening of the ankle joint in order to reduce pain and increase stability 156. 
 
 
 
Figure 9. Ankle and hip joint power graphs for healthy controls (black) and in children with 
JIA (grey) (Study IV). Generating ankle power is significantly reduced between healthy 
controls and JIA (p=0.001) while generating hip joint power does not differ between the 
groups. 
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An important finding in Study IV was that the ability to generate hip power in individuals 
with RA and JIA did not differ from healthy controls (Figure 9). This finding indicates that hip 
flexors were compensating for weaker plantarflexors. This is in contrast to healthy 
individuals in whom slower walking speed is associated with an increase in ankle power in 
relation to hip power (Figure 10) 115. The children with JIA in our sample had ankle and foot 
impairments which most likely restricted the ability to generate more ankle power. That hip 
muscles compensate for weaker ankle muscles has previously been described as an age-
related mechanism in older healthy adults 127 and as a compensatory mechanism in 
individuals with osteoarthritis 157 and neurological disabilities 158. This could possibly explain 
the slower walking speed seen in the children with JIA, since it has been suggested that to 
increase walking speed, increased generation of both hip and ankle power is required 128, 157.  
The possible consequences on pain and function of this power shift toward the hips are not 
known and warrant further investigation. Importantly, joint moments and powers can only 
be obtained through 3D gait analysis including force plates recoding. Thus, this technique is 
needed to evaluate these aspects in future studies and in clinical settings. In future studies 
the consequence of reduced ankle power on walking ability and sport participation for 
children with JIA would also be of interest to consider. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Black horizontal line represents the ankle/ hip power ratio in 86 healthy children 
walking at five different speeds, data adopted from Schwartz et al 2008 115. The vertical 
black bar represents the healthy controls in Study IV and the grey vertical bar represents the 
children with JIA. Free= self-selected walking speed.  
 
3.2.3 Effect of pharmacological treatment on gait dynamics 
The effect of reduced disease activity through pharmacological treatment on gait dynamics 
is not fully understood and is therefore an important aspect to evaluate in order to improve 
walking ability. In Study II, the effect of anti-Tumor Necrosis Factor-alpha (TNF-α) treatment 
was evaluated and in Study IV the effect of Intra-articular corticosteroid injection (IACI) in 
the foot and ankle was explored.  
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Effect of anti-tumor necrosis factor -α therapy  
Improvements in disease activity following anti-TNF-α treatment due to the fast-acting 
effects of these drugs are well known 84. The novel aspect of Study II was the evaluation of 
the effect of reduced disease activity, following anti-TNF-α treatment, on gait dynamics. In 
this pilot study we aimed to determine the effects of anti-TNF-α treatment on gait dynamics 
in individuals with RA. We hypothesized that gait dynamics would improve three months 
following treatment with anti-TNF-α, a hypothesis that was confirmed since gait dynamics 
improved as a result of treatment, however not to the levels of healthy controls. 
As commonly shown in studies evaluating the effect of biologic therapy, significant 
improvements in Study II were seen in measures of disease characteristics such as; HAQ, 
HAQ Pain, HAQ Global, DAS28-CRP, ESR, CRP,28 joint count following treatment with anti-
TNF-α (Study II). Moreover, participants reported less pain during walking after anti-TNF-α 
treatment: VAS median difference (IQR) =11 (0–21) (p = 0.05). 
Gait dynamics, both with respect to kinematics (GDI p= 0.04), kinetics (GDI-k p=0.05) and 
spatiotemporal parameters, improved following therapy (Study II). However, despite 
improvements in gait dynamics as a result of treatment gait deviations persisted three 
months after anti-TNF- α treatment (three months scores: mean GDI 91 (SD 12), mean GDI-k 
93 (SD 19). A meaningful change in GDI (>5 GDI units) was evident in only five out of 16 
patients. Of these five patients, four had a baseline GDI score below 90 and there was a 
moderate to good negative correlation between percentages of improvement in GDI after 
anti-TNF-α compared to GDI before treatment (rs = –0.71, p = 0.002). This result indicated 
that those with lower baseline value improve the most.  
As a result of anti-TNF-α treatment a majority of the patients increased their walking speed, 
with a mean increase of 8% (Study II). This increase in walking speed was in accordance with 
other studies which evaluated the effect of pharmacological treatment on gait dynamics 10, 
26, 27. Oda et al. (2014) evaluated gait dynamics six months following treatment with anti-
TNF–α, and reported an increase in walking speed of 22% 27. This more pronounced 
improvement in speed could be due to the longer follow-up time and the lower baseline 
scores compared to Study II. Both studies were e-published in 2013, and no prior studies 
evaluating the effect of anti-TNF-α treatment were identified.  The results from both studies 
are based on data from small sample sizes and conclusions should be drawn cautiously. 
Moreover, many participants had established disease with disease durations that extend to 
before the introduction of biologic therapy. Together, the two studies touch on an 
important aspect; on average, gait deviations persist despite treatment with advanced 
pharmacological therapy. Future studies are needed which include longitudinal analysis of 
gait dynamics in individuals starting treatment with biologic therapy in early disease and 
should preferably combine gait dynamics with ultrasound and x-rays to identify those at 
greater risk of gait deviations despite good response in disease activity. Moreover, measures 
of walking disability should be obtained simultaneously to further outline the relationship 
between gait dynamics and walking ability.   
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Effect of intra articular corticosteroid injections 
The aim of Study IV was to evaluate the effect of IACI on gait dynamics and patient-relevant 
outcomes in children with JIA with foot and ankle synovitis. The novel aspect of this study 
was the evaluation of gait dynamics and foot-related disability after IACI treatment in the 
era of biologic therapy, not previously evaluated. We hypothesized that gait dynamics was 
compromised in children with JIA who had foot involvements and that gait dynamics would 
improve with treatment, but not to the level of controls. However, we found that, as a result 
of IACI treatment, improvements were identified in foot-related disability and inflammatory 
joint symptoms but gait dynamics were unchanged. 
As expected due to the proven effect of IACI, the number of joints with active arthritis 
improved significantly (p<0.001) (Study IV). Foot-related disability improved in the 
JAFIimpairment (p=0.001) and JAFIactivity subscales (p=0.023) following treatment, but not in the 
JAFIparticipation subscale (p=278) (Table 3, Study IV). Importantly, despite improvements, 70% 
of the included children experienced continued foot-related disability at three months 
following treatment. These findings are in accordance with others who have highlighted the 
need for improved foot care in children with JIA 67, 69. Given the high occurrence of children 
with ankle and foot involvement (Study III) and the persistent problems following medical 
treatment (Study IV) we recommend that foot-related disability is routinely assessed in 
clinical practice 69.  The CHAQ walking scale may be used to identify walking disability but 
might not be sufficient to detect foot disability, and therefore, to address this, the CHAQ 
might be complemented by the JAFI. 
Following treatment, there was no statistically significant improvement in self-rated pain 
during walking over the three evaluations (p=0.135) (Study III). This was surprising and in 
contrast to Broström and co-workers (2004) who found that pain significantly decreased as 
a result of IACI treatment 10. Our results could be influenced by general scoring difficulties 
among our sample and the rating by one individual who rated highly increased pain 
following treatment. Effort was made to only include pain in lower extremity while walking, 
thus, pain in hands and shoulders should not be reported. However, we still acknowledge 
that generalized pain could have influenced this result 151. 
We find that the most important result from Study IV was that gait dynamics did not change 
following treatment. Most aspects of gait dynamics were, however, deviant compared to 
healthy controls following IACI treatment (Table 4, Study IV). This finding was in contrast to 
a study by Broström and co-workers (2004) where pain, walking velocity and joint moments 
improved as a result of IACI treatment 10. Importantly, gait deviations were more prominent 
after IACI treatment in their study as compared to baseline scores in Study IV. The two 
cohorts are interesting to compare since they were recruited from the same hospital but 
data collection was separated by ten years 10. We speculate that this improved general level 
of gait dynamics seen in our study was related to improved therapeutic options and 
strategies. An important strength with Study IV was that the included children were under 
general anesthesia during the IACI, and fluoroscopy and contrast enhancements were used 
to ensure an optimal needle placement and treatment effect. In future studies it would be 
of interest to evaluate the impact of gait dynamics on more demanding activities, such as 
jumping, running and sport participation 159. 
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3.2.4 Gait quality in relation to walking speed, pain, disease activity, 
and physical disability  
Integrating gait dynamics into studies of patient’s experiences of walking could expose 
factors contributing to walking disability 8. In Study IV, presence of gait deviations was 
related to walking disability in children with JIA. In adults with RA, gait deviations was 
somewhat related to walking speed but not to physical disability, pain and disease activity 
(Study I) (Figure 11). In the following section relationships between GDI and other outcome 
measures will be discussed. 
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Figure 11. Schematic overview of results from Studies I, II and IV. Relationships within 
individuals with RA and JIA between GDI and other outcome measures using an ICF context. 
 
 
In adults with RA, the GDI was partly influenced by walking speed. However, RA-related 
pathology was a greater contributor to the lower GDI scores than speed (Study I). It has 
previously been shown that the GDI score drops in healthy individuals who walk slowly 133. 
As individuals with arthritis commonly walk with reduced speed, the question regarding 
how much of the assessed gait deviations that were primarily related to speed has been 
raised 13, 125, 126. In order to evaluate the effect of walking speed on GDI in adults with RA 
(Study I), we calculated the GDI scores twice. In relation first to healthy controls walking at a 
self-selected speed and second to healthy controls walking at a speed matched to the speed 
of the adults with RA. Our results showed a significant improvement in average GDI of 
approximately 4 GDI units after speed matching, from 88 (SD 9) to 92 (SD 9) (p=0.017). As 
illustrated (Figure 2 in Study I) this difference was most obvious for adults with RA walking at 
very slow speed 115 which included about 40% of the actual sample. However, since the 
speed–matched GDI scores for the RA group remained significantly reduced (mean GDI 92 
(SD 9) as compared to controls (mean GDI 100 (SD 10))), factors other than speed, such as 
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pain, deformities, and compensatory walking strategies may contribute to impaired gait 
quality 17, 18. 
In Study I, we concluded that the GDI scores were not related to pain. This result was 
surprising since others have demonstrated relationships between deviant gait patterns and 
pain 160, 161. Generalized pain has also been strongly associated with walking disability in 
individuals with RA 151. In our study self-reported pain in the lower extremities during 
walking was analyzed while other studies have used assessments of global pain, also 
including upper extremities. Even though painful joints may lead to altered gait 
characteristics, gait patterns are probably also influenced by muscular weakness, feelings of 
instability and deformities 22, 162. The results in Study I could also be influenced by our 
approach in dividing pain scores into two groups containing low and high levels of pain 
respectively or by using a measure of overall gait quality, as both approaches reduced the 
variability in the parameters.  
We found that gait deviations and disease activity were not related to one another (Study 
II). The relationship was evaluated by a correlation analysis between GDI and DAS28-CRP 
before (rs = 0.09, p = 0.75) and approximately three months after treatment with anti TNF-α 
treatment (rs = 0.07, p = 0.8) (Study II). The finding was unexpected since increased disease 
activity has been related to both gait deviations 9, 12 and walking disability 151 in previous 
studies. The participants in Study II had established disease and a median disease duration 
of 9.5 years (interquartile range: 4.6-20.6) with potential joint destructions and deformities 
affecting gait patterns. Joint destruction and deformities are a consequence of increased 
disease activity but was not assessed in this thesis. It is, however, strongly recommended to 
consider this in future studies, since associations between structural deformities and gait 
dynamics have been identified previously 12.  
While the main focus of this thesis was on the presence of gait deviations, the link to 
walking or physical disability was considered (Study I and IV). An important finding was that 
the CHAQ walking subscale has the potential to be used to identify children with gait 
deviations (Study IV). Children reporting much difficulty with walking (CHAQ walking 
subscale) at baseline had more gait deviations as compared to children reporting less 
walking difficulty (Figure 9A and B) (Study IV). In the group reporting much difficulty with 
walking at baseline both GDI (p= 0.009) and ankle/hip power ratio (p= 0.004) differed from 
healthy controls. Three weeks following treatment the GDI and ankle/hip ratio did not differ 
from healthy controls, however, at the three months follow-up GDI returned to a 
significantly lower score, p=0.02. This improvement at three weeks, although not significant, 
could be attributed to the fast treatment effect of IACI 91. Importantly, we found that 
children reporting “no difficulty” with walking before IACI treatment had similar level of gait 
quality as healthy controls (Figure 12 A and B). Thus, the CHAQ walking subscale has the 
potential to be used to identify children with gait deviations (Study IV). Moreover, this result 
points to gait dynamics being an important factor to consider when assessing walking 
disability in individuals with arthritis. Future research including greater sample sizes is 
warranted to confirm this result.  
 
No association was found between gait quality (GDI) and physical disability, as assessed by 
the HAQ (Study I). This result strengthens what was already known from a study by Weiss et 
al. who correlated gait parameters (e.g. max knee flexion, max ankle plantarflexion) to the 
HAQ and found mostly weak correlations 11. 
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There are several reasons for this difference in results found in Studies I and IV of 
associations between gait dynamics and disability. In Study I the sample was dichotomized 
and in Study IV the sample was divided into three groups. Study I had a cross-sectional 
design while in Study IV, GDI scores following treatment were related to baseline scores. In 
Study I the total HAQ score was used and in Study IV the walking dimension from the CHAQ 
was used. While the HAQ and CHAQ are considered a gold standard for assessing physical 
disability in RA/JIA, and are widely used, it should be noted that the HAQ and CHAQ include 
both upper and lower extremity activities 103, 104. Thus, HAQ and CHAQ-scores are influenced 
by upper extremity activities not incorporated into the GDI. Study I was a retrospective 
analysis and therefore only the total HAQ scores were accessible. The advantage of using 
the HAQ and CHAQ walking subscale as a measure of walking disability is facilitated by the 
common use and good acceptance of the HAQ and CHAQ in clinical settings. Both the HAQ 
and the CHAQ have, however, been criticized for having ceiling effects 163, and the HAQ 
walking scale for low validity 105. Given the high level of gait function found in the children 
with JIA in Study IV, this could have influenced the results and the validity of using the CHAQ 
walking subscale as a measure of walking disability may be questioned. In future analysis, 
the use of other questionnaires specifically designed to assess walking disability in 
individuals with arthritis may be considered. 
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Figure 12. GDI (A) and ankle/hip power ratio (B) grouped according to reported walking 
difficulty (CHAQ walking dimension) before IACI treatment (Study IV). Pretreatment = white 
boxes, post 3weeks = grey boxes, post 3 months = dashed/grey boxes. Number of 
participants represented in boxes in figure A(B) pre/3weeks/3months; “no difficulty” = 
13/13/13(13/13/13), “some difficulty” =19/15/17 (19/14/14), “much difficulty” =11/9/9 
(11/8/8). The horizontal line represents the median value for healthy children for (A) GDI and 
(B) ankle/hip power ratio.* Statistical difference from healthy control. 
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3.3 METHODOLOGICAL CONSIDERATIONS 
3.3.1 Samples and study designs 
The use of already existing data, such as the retrospective analysis in Study I, has advantages 
– such as being less time consuming – but it also has disadvantages: missing data, inability to 
include additional data and uncertainty of how data have been gathered. Our decision to 
exclude those with an outdated HAQ score resulted in reduced number participants which 
could have affected the results. Individuals with RA in the database at the Karolinska 
University Hospital, Stockholm were included when they completed a 3D gait analysis for a 
cross-sectional or a pre/post- treatment study 11, 129. Moreover the participants are 
heterogeneous in terms of disease duration and pharmacological therapy, which, taken all 
together, restricts generalization.  
 
Study II and IV evaluated the effect of well-established pharmacological interventions on 
gait dynamics in prospective pre-post studies. To evaluate the true effect of pharmacological 
intervention on gait dynamics a non-treated control group would have been preferable, to 
ensure that the changes in gait deviations were related to the pharmacological treatment 
and not to other factors. However, a control group including untreated individuals with RA 
and JIA with similar levels of disease activity would have been strongly unethical due to the 
proven effect of the drugs and the known negative effects of not receiving treatment when 
qualified to do so 84. The included sample in Study II is small and the inclusion period spans 
over six years. Thus, conclusions from this study should be drawn with care. Children with 
JIA participating in Study IV were included based on foot involvement. It has been suggested 
that foot involvement is predictive of more progressive disease 65, 68, 164, thus our sample of 
children with JIA most likely represents a group with a more severe disease than the 
average patient. Sixty-five percent of the children with JIA had polyarthritis, a high 
percentage as compared to the total JIA population (40% have polyarticular disease) 131. 
Only children injected under general anesthesia using fluoroscopy and contrast 
enhancement were included due to the proven superior result of injecting small joints in the 
foot using this method 88.  
 
The results from Study III are based on data from a population based prospective 
longitudinal cohort, a design which supports the validity of the results. The cohort is 
multinational and includes 500 children from well-defined geographic regions in Sweden, 
Norway, Denmark and Finland. All ILAR categories were represented, even if the number of 
patients in some categories was small, restricting subgroup analysis. Effort was put into 
making the study as population based as possible, there are however always the risks of 
missing individuals, of individuals refusing to participate, of individuals being undiagnosed or 
wrongly diagnosed, and of cases referred to specialists other than the participating centers. 
Despite the study length of eight years only 12% were lost to follow-up, mostly older 
children transferred to adult rheumatology care 131. 
3.3.2 Measuring gait dynamics 
When analyzing gait with 3D gait analysis in individuals with RA and JIA there are several 
methodological issues to consider. Morning stiffness is a common problem and may affect 
gait pattern in individuals with RA. Systematic variations throughout the day have been 
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described with improved gait dynamics later in the day 165. Gait analyses included in this 
thesis are conducted in the afternoons, except for a few individuals reporting no morning 
stiffness and who preferred to come to the gait analysis laboratory in the morning.  
 
All gait analysis was conducted with the participants walking barefoot. This approach could 
have elevated the degree of gait deviations. Some of the adults with RA mentioned that 
they, due to considerable foot impairment, never walked without shoes. Barefoot walking 
was not a problem that any of the children addressed in Study IV. Walking with footwear 
could be an alternative, but the potential impact of different shoe designs, time walked in 
the actual shoes, and insoles would have been confounding factors in such analysis.  
 
In this thesis the choice was made to have participants walking at self-selected speed, as 
opposed to standardized cadence indicated by a metronome. From a clinical standpoint, 
self-selected speed is the most relevant as it is related to everyday activities, requires 
minimal energy expenditure, and has been associated with increased stability while walking 
13, 166. Before capturing gait dynamics the participants were instructed to repeatedly walk 
back and forth on the 10 meters walkway until they walked at their preferred pace. In Study 
IV, parents of the children were consulted to ensure that a typical gait pattern and speed 
was captured. However, almost all aspect of gait are sensitive to walking speed and 
conclusions about change in gait dynamics following interventions and between groups 
must be drawn with this in mind 115. 
 
Gait analysis within this thesis was conducted by one of two experienced physiotherapists 
(EWB and ACE). Effort was made to ensure consistency between the assessors in marker 
placement and instructions to patients. In 3D gait analysis several aspects contribute to the 
achieved levels of reliability. First, aspects related to the assessor such as adequate training 
in marker placement and underlying biomechanical model, second aspects related to the 
patients, such as ability to cooperate and cognition 155. It is generally found that gait data 
from adults is less variable than from children 167 and younger children were found to be 
more variable than older children 168. This coincides well with the impression the assessors 
gained at the gait analyses conducted for this thesis. However, despite many possible 
sources of error in 3D gait analysis it is clinically accepted that reliable measures are 
achievable and can be summarized as: Movements in the sagittal plane are most reliable 
followed by movement in the frontal and lastly in the transversal plane 155.  In future 
studies, the reliability of the GDI, which incorporates movements from all three anatomical 
planes, should be addressed. 
 
The aim and focus of the present study was on gait dynamics but in future studies inclusion 
of more demanding activities might be considered. Walking inside a gait laboratory is a 
simple physical activity with no obstacles, no inclinations and only short distances. It could 
be argued, especially for the children, that walking within these conditions is not a 
sufficiently challenging activity. However, impairments in gait dynamics were identified in 
both adults with RA and children with JIA indicating that more challenging activities such as 
outdoor walking, jumping and sport participation most likely amplify the deviations 169.  
 
In this thesis the GDI was found to be a useful measure of overall gait quality in individuals 
with RA and JIA. The GDI scores can be used as a “stand alone” measure but there are 
several disadvantages related to the GDI to being considered. GDI scores are not informative 
about the cause or the nature of the deviation. The GDI is a distance measure that 
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quantifies how far the kinematics of a specific stride is from the mean kinematics of the 
control group 119. There is no direction associated with this distance, meaning that the 
actual deviations (e.g. increased hip flexion, decreased dorsiflexion, etc.) cannot be deduced 
from the measure itself. Thus, to understand which gait deviations cause the lower GDI 
score, it is imperative that the gait parameters incorporated into the GDI scores are 
displayed (Figure 5) or that univariate measures (max, min, ROM, timing) are extracted from 
the gait data. 
3.3.3 Measuring physical disability and pain 
In Studies III and IV, physical disability was reported by children or their parents, depending 
on the child´s age. Using a proxy version of a questionnaire challenges interpretation since it 
could not be ensured that it is the child´s belief’s being documented 170. In children with JIA, 
the discordance between physicians and parents´ estimation of a child’s physical ability has 
been shown to vary with the severity of disease and pain 171. In Study IV, the questionnaires 
at the two separated evaluations were completed by the same parent to ensure 
consistency. There is no “gold standard” solution to the proxy problem and what strategy to 
use should be related to the study design and the intended use of the data 170.  
 
In the JAFI some statements are positively formulated and others negatively formulated to 
make careful consideration of each statement necessary. This design was carefully explained 
in advance but might still have led to a higher proportion of reported foot-related disability, 
a concern also raised in earlier studies 69.  
Measuring pain is challenging due to its subjective nature and may be complicated due to 
feelings of anxiety or by the age of the subjects 136. In Study IV, pain during walking was 
reported either by a VAS scale (children from eight years of age) or by the faces pain scale 
(children below eight years of age) 136. The scales were thoroughly explained using a 
standard interactive procedure to help the children differentiate between, for example pain 
and stiffness. A few children still encountered scoring difficulties. For example, some of the 
children scored equally low levels of pain before and after IACI treatment, but after 
treatment they stated that “now I am in no pain!” This could be a potential reason why pain 
during walking did not improve with treatment as previously described 10. Whilst most 
participants experienced improvements, one participant reported increased pain after 
treatment. Due to the small sample size, we did not exclude the subject from the analysis. 
3.4 STATISTICAL CONSIDERATIONS 
When performing statistical analyses of walking it is important to remember that walking is 
a bilateral activity including two legs, not independent from each other. In this thesis 
different approaches have been used to handle this issue. In Studies I, II and in some of the 
analyses in Study IV, mean values of left and right GDI scores were used. This approach was 
taken for several reasons: there were no statistical differences between left and right sides 
(legs) and included individuals with RA and JIA had bilateral involvement. In Studies I, II and 
IV GDI scores were related to other measures considering general aspects of physical 
disability and disease activity. In this context the averaged GDI scores were thought to 
represent overall gait pattern. Other possible approaches to handle bilateral data include: to 
randomly select one of left and right observation or to use the lowest GDI scores, 
representing worst gait pattern. A personal reflection is that in individuals with arthritis, the 
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side with lowest GDI is not always the most involved side or even the treated side, posing 
challenges to this choice of analysis. In Study IV, evaluating the effect of foot IACI in children 
with JIA over a three months period, the interdependence (correlation) between the sides 
(legs) over the three evaluations was accounted for by using a linear mixed model 172. 
Another advantage with this method is that those participants with missing data are kept in 
the analysis.   
 
In Study IV, 37% of the included children increased their medication during the study period 
because of unacceptable levels of disease activity (e.g. changed or started new DMARD or 
biologic treatment). Due to the small sample size this factor could not be considered as a 
covariate in the statistical analysis, possibly affecting the results. With respect to gait 
dynamics the effect was probably small given that gait dynamics did not change following 
treatment, not for the total group, nor for the polyarticular or the oligoarticular group. 
Another possible way to handle this would be to dichotomize the children into one group 
with an increase in general medication treatment and another group with stable treatment. 
However, the result from such an approach would be challenging to interpret due to the 
heterogeneity in what new medical treatment was given (fast or slow acting drug) or when 
it was given (at what time point in relation to the follow-up times). 
 
In Study I, the ICC-values between three strides were shown to be excellent and this could 
be influenced by what strides were included in the analysis. The ICC is dependent upon 
heterogeneity of the group and will be high if the variance of GDI scores between subjects is 
higher than within subjects 147. In this study three strides were selected based on visual 
inspection with a potential risk of not being representative. However, both the adults with 
RA and adult controls were walking with a consistent gait pattern, thus the excluded strides 
showed a consistent pattern with the included strides.  In future studies, however, a random 
selection of strides or inclusion of all available strides should be considered. 
3.5 LIMITATIONS 
As with most studies, the results from the studies included in this thesis have weaknesses 
that restrict generalization. Some of the limitations have already been discussed and others 
are outlined below.  
 
An important limitation of Studies I-IV was that arthritis was clinically evaluated without 
verification with ultrasound or other imaging modalities, which might have led to an 
underestimation of the number of affected joints, as ultrasound has proven superior in 
detecting synovitis 173. Moreover, evaluating foot arthritis using ultrasound may have added 
further information such as distinctions between talocrural, subtalar and tarsal involvement 
and detecting subclinical inflammation.  
 
Gait dynamics may be altered for various reasons including the presence of deformities, an 
aspect not considered in the present thesis. In future studies evaluations of deformities in 
lower limbs could be of value when evaluating the impact of inflammatory and mechanical 
aspects on gait dynamics and walking disability 16.  
 
The aim of Study II and IV was to evaluate overall gait quality in relation to disease and to 
pharmacological treatment. However, it is well known that both adults with RA and children 
with JIA have inflammation from the small joints in foot. Deviations in these joints are not 
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covered in the present studies since the foot was modeled as rigid segment and only 
motions at the ankle joint were considered. This approach, to not include the different 
segments of the foot in the 3D gait analysis, may have led to an underestimation of gait 
deviations 13.  
 
In Study I, both GDI and speed-matched GDI scores for adults with RA and healthy adults 
were calculated using a reference set based on children. The pediatric reference set was 
used because of the wide range of available speeds. A similar multispeed reference set was 
not available for adults. We acknowledge that an adult reference set would have been ideal 
but the mean values for our adult controls were, however, very close to 100 (10) indicating 
consistent gait pattern between the reference set and the adult controls participating in this 
studies. 
3.6 CONCLUSIONS AND CLINICAL IMPLICATIONS 
This thesis highlights the importance of considering gait quality when evaluating walking 
disability in individuals with RA and JIA; we recommend the use of measures of overall gait 
quality, such as the GDI, to quantify gait deviations. The GDI adds a quality aspect of walking 
function to more commonly evaluated aspects of function within arthritis care such as 
performance-based and self-reported function. Moreover, the GDI may facilitate 
comparisons of gait dynamics between groups, over time and following intervention.  
 
In individuals with RA and JIA, gait quality is compromised despite potent pharmacological 
interventions. This indicates that gait quality should be considered to further evaluate the 
relationship between arthritis, gait dynamics and walking disability. Anti-TNF-α treatment 
improved gait dynamics in adults with RA. Significant gait deviations were, however, still 
present after treatment. As a result of IACI treatment in children with JIA, improvements 
were identified in foot-related disability and inflammatory joint symptoms, but gait 
dynamics were unchanged. Children with polyarticular disease and those reporting much 
difficulty with walking prior to treatment had the most impaired gait function and should be 
monitored carefully. 
 
We suggest that ankle arthritis should be recognized in the assessment of prognosis and 
choice of treatment strategy in JIA, since it predicts a polyarticular disease course in young 
children and is associated with failure to achieve remission. Moreover, we recommend that 
foot involvement is routinely assessed in clinical practice, given the high occurrence of ankle 
and foot involvement in JIA and the persistent problems with foot-related disability and gait 
dynamics following pharmacological intervention. The CHAQ walking scale may be used to 
identify walking disability, but might not be sufficient to detect foot disability. To address 
this, CHAQ might be complemented by the JAFI. 
3.7  FUTURE PERSPECTIVES 
In individuals with RA research on gait dynamics has predominantly been focused on the 
foot with measures of foot kinematics obtained through the use of biomechanical foot 
models 17. It has, however, been suggested that the involvement of larger joints contribute 
to a higher extent to walking disability than the involvement of smaller joints 151. Therefore, 
the GDI, incorporating gait dynamics from pelvis, hip, knee and ankle, could reflect the 
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impact of specific foot impairments on overall gait quality and has the potential to serve as 
an additional measure of overall diseases severity, just as DAS28 and HAQ currently do for 
disease activity and physical disability respectively.  
 
Future analysis of gait dynamics in prospective longitudinal studies with individuals starting 
new pharmacological treatments are needed to help in identify those at greater risk of gait 
deviations despite good response in disease activity. However, several factors contribute to 
walking disability in individuals with RA and JIA and, above pathology and gait dynamics, 
individuals experiences of walking should be considered 16. In future studies this could, for 
example, be enhanced by using a mixed methods approach integrating both quantitative 
and qualitative aspects 8. Thereby the understanding of factors contributing to walking 
disability can be revealed and walking ability improved.  
 
We suggest that ankle arthritis should be recognized in the assessment of prognosis and 
choice of treatment strategy in JIA. Beyond the risk of extended disease and failure to 
achieve remission identified in Study III, the results from Study IV identified gait deviations 
as a persistent problem in children with JIA and ankle involvement. Easily administered 
instruments, such as questionnaires, have a great screening potential, and preliminary 
results from Study IV suggest that the CHAQ walking subscale might be useful identifying 
individuals with persistent gait deviations. This, however, needs to be further assessed in 
future studies. 
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